

Copper-Catalyzed C(sp²)-H Difluoroalkylation of Aldehyde-Derived Hydrazones with Diboron as Reductant

Miaolin Ke, and Qiuling Song

J. Org. Chem., **Just Accepted Manuscript** • Publication Date (Web): 29 Mar 2016

Downloaded from <http://pubs.acs.org> on March 29, 2016

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.




Copper-Catalyzed C(sp²)-H Difluoroalkylation of Aldehyde-Derived Hydrazones with Diboron as Reductant

Miaolin Ke and Qiuling Song*

Institute of Next Generation Matter Transformation, College of Chemical Engineering,
College of Materials Science & Engineering at Huaqiao University

Fax: 86-592-6162990; email: qsong@hqu.edu.cn

Abstract



An efficient and general method for C(sp²)-H difluoroalkylation of aldehyde-derived hydrazones via Cu(II)/B₂pin₂ catalyzed reaction between difluoroalkyl bromides and hydrazones was developed. In this reaction, both aromatic and aliphatic aldehyde-derived hydrazones could be achieved in good to excellent yields. For some heteroaromatic aldehyde-derived hydrazones, two fluoroacetates could be introduced onto the final products. Preliminary mechanism study manifested that a difluoroalkyl radical via SET pathway was involved in the reaction. And catalytic diboron reagent plays an indispensable role in this transformation.

INTRODUCTION


The incorporation of fluorinated functional groups into organic molecules has generated extraordinary research activity because of the enhanced metabolic stability, lipophilicity,

1
2
3 reactivity of the molecules compared to their nonfluorinated counterparts.¹⁻³ Although
4
5 significant advances have been made on functionalized fluoroalkylation of aromatic
6
7 compounds,⁴⁻⁶ efficient and general methods for the synthesis of hydrazones containing
8
9 difluorinated functional groups with high stereoselectivity through copper-catalyzed
10
11 transformations are relatively rare.^{9c} Aldehyde-derived hydrazones are an important
12
13 intermediate in organic synthesis.⁷ Conceptually, introduction of the CF₂ group into such a
14
15 structural motif would open a good possibility to discover some novel bioactive molecules.
16
17
18
19


20
21 Recently, the fluoroalkyl radical addition of aldehyde-derived hydrazones has become an
22
23 efficient tactic to synthesize α,α -difluoro- β -ketoesters. There are several known methods to
24
25 achieve fluoroalkylated aldehyde-derived hydrazone compounds: a) visible-light
26
27 photoredox-catalyzed cross coupling between aldehyde hydrazones and fluoroalkyl reagent
28
29 (for example, with iridium or gold catalysts);⁸ b) transition-metal-catalyzed cross coupling of
30
31 aldehyde-derived hydrazones and fluoroalkyl halides.⁹ In the latter case, Monteiro and
32
33 co-workers reported an elegant Pd-catalyzed C-H alkylation of aldehyde-derived hydrazones
34
35 with functional difluoromethyl bromides.^{9d} Very recently, they also reported a Cu-catalyzed
36
37 difluoroalkylation of aldehyde hydrazones.^{9e} However, in both cases aliphatic
38
39 aldehyde-derived hydrazones failed to provide difluoroacetated hydrazones, and expensive
40
41 metals or ligands were essential to the success of the reactions. Inspired by our recent work on
42
43 the Cu(II)/B₂pin₂-catalyzed hydrodifluoroacetylation of alkynes or phenylpropionic acids with
44
45 bromodifluoroacetate, in which difluoroalkyl radicals were generated via a single-electron
46
47 transfer (SET) pathway (scheme 1a),¹⁰ we envisioned that C(sp²)-H difluoroalkylation of
48
49 aldehyde-derived hydrazones might be synthesized via the same novel radical generation
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 system: Cu/B₂pin₂, undoubtedly and ideally, if catalytic amount of B₂pin₂ was enough for the
5
6 success of the transformation instead of stoichiometric amount, this reaction will become
7
8 more attractive. Most interestingly, we successfully obtained C(sp²)-H difluoroalkylation of
9
10 aldehyde-derived hydrazones with our Cu(II)-B₂pin₂ catalytic system in which only 30 mol%
11
12 of B₂pin₂ was enough for this transformation and aliphatic aldehyde-derived hydrazones can
13
14 also smoothly difluoroalkylated.
15
16
17
18
19

20 a) Copper-catalyzed hydrodifluoroalkylation of alkynes or alkynyl carboxylic acids



28 b) This work




36 Scheme 1. Synthetic methods involving •CF₂COOEt radical with Cu(II)/B₂pin₂ catalyst
37
38 system.
39

40 RESULTS AND DISCUSSIONS

41
42
43 In order to examine our hypothesis, our investigation commenced with aldehyde hydrazones **1**
44
45 and ethyl bromodifluoroacetate **2** as the model substrates with 1 equivalent of B₂pin₂
46
47 according to our previous work.¹⁰ To our delight, the desired difluoroalkylated aldehyde
48
49 hydrazones compounds **3** was obtained in 52% isolated yield at 80 °C using 10% CuBr₂ as
50
51 catalyst, 10% DTBDPy as ligand, 1 equivalent of B₂pin₂ as additive and 2 equivalent of KOAc
52
53 as base in 1,4-dioxane. Subsequently, other reaction parameters, such as base, loading of
54
55
56
57
58
59
60

1
2
3
4 B₂pin₂, Cu salt, ligand, reaction atmosphere were surveyed (table 1, entry 1-24). Among the
5
6 tested bases (table 1, entry 1-7), NaHCO₃ showed the superior activity over others (KOAc,
7
8 K₂CO₃, Na₂CO₃, NaOAc, KF, Cs₂CO₃), providing the desired product **3** in 93% isolated yield
9
10 (table 1, entry 1-7). Surprisingly, we found that the loading of B₂pin₂ could be dropped to 30
11
12 mol% without deteriorating the yield (table 1, entry 9-10). However, lowering the loading of
13
14 B₂pin₂ significantly reduced the yield (table 1, 83%, entry 8). As we can see, CuCl, CuBr,
15
16 CuCl₂ and Cu(OAc)₂ were all good catalysts when combined with ligand L1, yet CuBr₂ was
17
18 the best among them (table 1, entry 11-14). In terms of other ligands, the yields of the desired
19
20 product dropped dramatically, and no desired one was observed when P ligand L5 was used in
21
22 the transformation (table 1, entry 15-18). Control experiments suggested that the additive
23
24 B₂pin₂ is indispensable to the reaction since no reaction occurred in its absence (table 1, entry
25
26 22). No desired product **3** was observed as well in the absence of copper catalyst, ligand or
27
28 base (table 1, entry 19-21), demonstrating that both copper salt, ligand and base play essential
29
30 roles for the promotion of the reaction. This reaction is anaerobic and could not proceed under
31
32 air or molecular oxygen (table 1, entries 23 and 24).
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Optimization of the reaction conditions.


entry	catalyst (10 mol%)	ligand (10 mol%)	base (2 equiv)	yield (%)
1	CuBr ₂	L1	KOAc	52
2	CuBr ₂	L1	K ₂ CO ₃	72
3	CuBr ₂	L1	Na ₂ CO ₃	78
4	CuBr ₂	L1	NaOAc	77
5	CuBr ₂	L1	NaHCO ₃	96 (93)
6	CuBr ₂	L1	KF	34
7	CuBr ₂	L1	Cs ₂ CO ₃	30
8 ^a	CuBr ₂	L1	NaHCO ₃	83
9 ^b	CuBr ₂	L1	NaHCO ₃	>99 (96)
10 ^c	CuBr ₂	L1	NaHCO ₃	>99
11	CuCl	L1	NaHCO ₃	95
12	CuBr	L1	NaHCO ₃	89
13	CuCl ₂	L1	NaHCO ₃	93
14	Cu(OAc) ₂	L1	NaHCO ₃	91
15	CuBr ₂	L2	NaHCO ₃	75
16	CuBr ₂	L3	NaHCO ₃	18
17	CuBr ₂	L4	NaHCO ₃	8
18	CuBr ₂	L5	NaHCO ₃	NR
19	-	L1	NaHCO ₃	NR
20	CuBr ₂	-	NaHCO ₃	NR
21	CuBr ₂	L1	-	NR
22 ^d	CuBr ₂	L1	NaHCO ₃	NR
23 ^e	CuBr ₂	L1	NaHCO ₃	NR
24 ^f	CuBr ₂	L1	NaHCO ₃	NR

Reaction Condition: **1** (0.2 mmol), **2** (0.4 mmol), Cu salt (10 mol %), ligand (10 mol %), base (2 equiv.), B_2pin_2 (entry 1-7, 1 equiv), B_2pin_2 (entry 11-23, 30 mol%), dioxane (1 mL), at N_2 , 16 h. ^a B_2pin_2 (20 mol %). ^b B_2pin_2 (30 mol %). ^c B_2pin_2 (40 mol %). ^d under air. ^e under O_2 , ^f absence of B_2pin_2 . GC yield by using *n*-dodecane as an internal standard. The isolated yield was listed in parathesis.

In order to test the scope of the method, a variety of aldehyde-derived hydrazones was surveyed (scheme 2). A series of difluoroacetylated aldehyde hydrazones was obtained in

good to excellent yields with versatile substituents on the aromatic rings regardless of the electron-donating or electron-withdrawing nature (**3-12**). Notably, 4-*N,N*-dimethyl product **13** was obtained in good yield under our standard conditions. Moreover, the position of substituents on the aromatic ring has less impact on the reactions albeit *ortho* ones with relatively lower yields (**16-20**). With multiple substituents on the aromatic rings, the

Scheme 2. Substrate scope of aldehyde-derived hydrazones for difluoroacetylation.




^a Reaction Conditions: aldehyde-derived hydrazones (0.3 mmol), $\text{BrCF}_2\text{COOEt}$ (**2**) (0.6 mmol), CuBr_2 (10 mol %), DTBDPy (10 mol %), NaHCO_3 (2 equiv.), B_2pin_2 (30 mol %) dioxane (1 mL), 80 °C, 16 h, under N_2 in a Schlenk tube, all yields are those of isolated product. ^b Using 1 equivalent $\text{BrCF}_2\text{COOEt}$. ^c Using 2.5 equivalent $\text{BrCF}_2\text{COOEt}$. ^d Using CuCl_2 instead of CuBr_2 . The ratio in parenthesis is the *E/Z* ratio.

1
2
3
4 corresponding products were also obtained with good yields (**14-15**). However, the reaction of
5
6 naphthylaldehyde hydrazone gave a surprisingly low yield (**21**). Heteroaromatic
7
8 aldehyde-derived hydrazones were also compatible under the standard conditions (**22-28**),
9
10 interestingly, some bis-fluoroacetates were selectively synthesized from thiophene or furanyl
11
12 or benzothiophene aldehyde-derived hydrazones (**23-27**). Importantly, aliphatic aldehyde
13
14 hydrazones were good substrates in this transformation and the corresponding desired
15
16 products were obtained in decent yields, albeit with relatively low stereoselectivities (**29-33**),
17
18 which makes our method an alternative one for the reported Pd- or Cu-catalyzed
19
20 difluoroalkylation of aldehyde-derived hydrazones, in which aliphatic aldehyde-derived
21
22 hydrazones only rendered trace amount of desired products.^{9d, 9e} It needs to be pointed out
23
24 that our conditions were also applicable for the N,N-dimethyl aliphatic aldehyde-derived
25
26 hydrazone and 30% of corresponding product **30** was obtained. However, when
27
28 (E)-N-hexylidenemorpholin-4-amine was subjected under Monteiro's conditions^{9c} in the presence
29
30 of B₂Pin₂, the corresponding desired product was only obtained in 14% yield, much lower than the
31
32 one under our current standard conditions (49% yield).
33
34
35
36
37
38
39
40





41
42 Next, we investigated the scope of *N*-substituent aldehyde hydrazones and the scope of
43
44 difluoro reagents (scheme **3**). Delightedly, the reactions were not just restricted to
45
46 morpholine-derived hydrazones, phenylamine, piperidinyl and 4-methylpiperazinyl-derived
47
48 hydrazones were also suitable candidates for this transformations, with corresponding desired
49
50 products obtained in reasonable yields (**34-36**). Whereas the N-Bs (Bs = benzenesulfonyl)
51
52 hydrazones (**37**) and oxime hydrazones (**38**) failed to furnish the desired product, probably
53
54 due to their low HOMO level. Gratifyingly, the corresponding difluorinated hydrazone (**39**)
55
56
57
58
59
60

was obtained with excellent yield using bromodifluoroacetamide, which was prepared from bromodifluoroacetate **2** with phenylamine.¹¹



Scheme 3. Investigation of the effect of the N-substituents and bromodifluoroacetamide

Satisfyingly, this reaction could be easily scaled up to 5 mmol and desired product **3** was achieved in a high isolated yield of 86% in 1.4 gram (Scheme 4, eq 1), which illustrated the practicality and robustness of our transformation. Aldehyde-derived hydrazones is a facile important intermediate in organic chemistry which could be easily subjected for further structural manipulation. For instance, compound **3** could be hydrolyzed into *a,a*-difluoro- β -ketoester **40** in 88% yield (scheme 4, eq 2). And difluorinated hydrazine **41** was readily generated when compound **3** was subjected with lithium aluminum hydride in anhydrous THF (scheme 4, eq 3), in which ester group was also reduced simultaneously along with C=N bond to render an alcohol. Noteworthy, the ester group in compound **3** was transformed into hydroxyl group while the C=N double bond was untouched in compound **42** when compound **3** was treated with sodium borohydride (scheme 4, eq 4).




35
36

Scheme 4. The application of difluoroalkylation of aldehyde-derived hydrazones

37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Radical trapping experiments were subsequently performed in order to understand the mechanism of this Cu(II)/B₂pin₂-catalyzed C(sp²)-H difluoroalkylation of aldehyde-derived hydrazones. The desired product **3** was not obtained when radical scavenger 2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO) was added, instead, TEMPO-CF₂COOEt was generated in ca. 20% yield, implying that a radical pathway was involved in this reaction (eq 5). Furthermore, when 1-phenylstyrene (**43**) was added to the mixture of compound **1** and **2** under the standard conditions, desired product **3** was only formed in trace with 40% of compound **43** remained along with formation of compounds **44** and **45**. This result further confirmed the involvement of a free radical pathway in this transformation (eq 6).



On the base of the above control experiments, our previous work,¹⁰ as well as precedent reports,^{9c} a plausible mechanism is postulated (Figure 1). Initially, interaction between a Cu(II) salt **A** and B₂pin₂ generates a Cu(I)-Bpin species **B**.^{10, 12, 14} Subsequently, an electrophilic fluoroalkyl radical from bromodifluoro reagent is formed via bromide abstraction by the copper(I) complex **B** with concomitant generation of copper(II) **C**.^{10, 12b} The radical can be trapped by aldehyde-derived hydrazone to form the aminyl radical **D** which further converts into intermediate **E** via SET process.^{8, 13} Then the removal of proton eventually produces the desired product **3**.




Figure 1. Plausible mechanistic pathway.

1
2
3
4 In summary, we described a novel, efficient C(sp²)-H difluoroalkylation of
5
6 aldehyde-derived hydrazones via Cu(II)/B₂pin₂ catalyzed reaction between difluoroalkyl
7
8 bromides and hydrazones. A broad range of functional groups was tolerated well under
9
10 standard conditions with good to excellent yields. And aliphatic aldehyde-derived hydrazones
11
12 are also good candidates in this method to render the corresponding products, which make our
13
14 method as a complement protocol for the existing methods. Further applications about this
15
16 transformation are under investigation in our laboratory.
17
18
19

20 21 **EXPERIMENTAL SECTION**

22
23
24 **General information:** All reactions were accomplished in Schlenk tubes or round flasks
25
26 under an atmosphere of N₂. Column chromatography was performed over silica gel (200-300
27
28 mesh). ¹H NMR spectra were recorded on a 500 M spectrometer and chemical shifts (in ppm)
29
30 were referred to CDCl₃ (δ = 7.26 ppm) as an internal standard. ¹³C NMR spectra were
31
32 obtained by using the same NMR spectrometer and were calibrated with CDCl₃ (δ = 77.0
33
34 ppm). ¹⁹F NMR spectrometers were operated on the same NMR spectrometer (CFCl₃ as an
35
36 external standard and low field is positive). The following abbreviations were used to
37
38 illuminate the diversities: δ = chemical shifts, J = coupling constant, s = singlet, d= doublet, t
39
40 = triplet, q = quartet, m = multiplet. HRMS (EI) were measured with a quadrupole and TOF
41
42 mass spectrometers. CH₂Cl₂ was distilled from CaH₂. All reagents and solvents were obtained
43
44 from commercial suppliers, and used without further purification. Reactions were monitored
45
46 by thin-layer chromatography (TLC), GC or GC-MS analysis. The products were purified by
47
48 column chromatography on silica gel using petroleum ether and ethyl acetate as the eluent.
49
50
51
52
53
54

55
56 **The synthesis of aldehyde-derived hydrazones (1a -1ah)**¹⁵
57
58
59
60

1
2
3
4 Morpholin-4-amine (2.2 mmol), aldehyde (2.0 mmol) and anhydrous MgSO₄ (0.5 g) in
5
6 CH₂Cl₂ (10 mL) was stirred overnight at room temperature until consumption of the raw
7
8 material aldehyde (TLC tracking). After filtration of MgSO₄, the solvent was removed under
9
10 reduced pressure and the residue was subjected to column chromatography to give the
11
12 aldehyde-derivative hydrazone (**1a-1ah**) with good yields.
13
14

15
16 **General procedure for the synthesis of Difluoroalkylation of Aldehyde-Derived**

17
18 **Hydrazones.** aldehyde hydrazone (0.3 mmol), bis(pinacolato)diboron (30 mol%, 22.9 mg),
19
20 CuBr₂ (10 mol%, 6.7 mg), 4, 4'-Dibutyl-2, 2'-bi-pyridyl (10 mol%, 8.1 mg), NaHCO₃ (2
21
22 equiv, 50.5 mg) were added to a 25 mL of Schlenk tube under air. Then the mixture was
23
24 evacuated and backfilled with N₂ (3 times). Ethyl bromodifluoroacetate (2 equiv, 77 μL) and
25
26 dioxane (1 mL) were added subsequently. The Schlenk tube was screw-capped and put into a
27
28 pre-heated oil bath (80 °C). The reaction mixture was cooled to room temperature after
29
30 stirring for 16 h. After the reaction was finished, the mixture was concentrated under vacuum
31
32 to remove dioxane, and the residue was purified by chromatography on silica gel (petroleum
33
34 ether: ethyl acetate = 10:1-1:2) to afford the product.
35
36
37
38
39

40
41 (*E*)-N-(4-methylbenzylidene)morpholin-4-amine (**1a**).¹⁶ Afforded **1a** (390 mg, 96%) as a
42
43 white solid, m.p. 92-93 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.59 (s, 1H), 7.50 (d, *J* = 8.1 Hz,
44
45 2H), 7.16 (d, *J* = 7.9 Hz, 2H), 3.89 (t, *J* = 5.0 Hz, 4H), 3.16 (t, *J* = 5.0 Hz, 4H), 2.35 (s, 3H).
46
47 ¹³C{¹H}NMR (125 MHz, CDCl₃): δ 138.3, 136.7, 133.2, 129.2, 126.2, 66.5, 52.0, 21.3.
48
49

50
51 (*E*)-N-benzylidenemorpholin-4-amine (**1b**).¹⁷ Afforded **1b** (360 mg, 95%) as a white solid,
52
53 m.p. 68-69 °C. ¹H NMR (500 MHz, CDCl₃): δ 7.65 – 7.58 (m, 3H), 7.35 (t, *J* = 7.5 Hz, 2H),
54
55 7.29 (ddd, *J* = 7.3, 3.8, 1.2 Hz, 1H), 3.89 (t, *J* = 5.0 Hz, 4H), 3.18 (t, *J* = 5.0 Hz, 4H).
56
57
58
59
60

$^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 136.2, 135.9, 128.5, 128.3, 126.2, 66.4, 51.8.

(*E*)-*N*-(4-methoxybenzylidene)morpholin-4-amine (**1c**).¹⁸ Afforded **1c** (396 mg, 90%) as a white solid, m.p. 74-75 °C. ^1H NMR (500 MHz, CDCl_3) δ 7.58 (s, 1H), 7.54 (d, J = 8.8 Hz, 2H), 6.88 (d, J = 8.8 Hz, 2H), 3.88 (t, J = 5.0 Hz, 4H), 3.81 (s, 3H), 3.13 (t, J = 5.0 Hz, 4H).

$^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 159.9, 136.7, 128.7, 127.5, 114.0, 66.4, 55.2, 52.1.

(*E*)-*N*-(4-fluorobenzylidene)morpholin-4-amine (**1d**).^{8a} Afforded **1d** (408 mg, 98%) as a white solid, m.p. 77-78 °C. ^1H NMR (500 MHz, CDCl_3) δ 7.61 – 7.53 (m, 3H), 7.03 (t, J = 8.7 Hz, 2H), 3.88 (t, J = 5.0 Hz, 4H), 3.15 (t, J = 5.0 Hz, 4H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 162.8 (d, J = 246.3 Hz), 135.0, 132.1 (d, J = 2.5 Hz), 127.7 (d, J = 5.0 Hz), 115.4 (d, J = 8.8 Hz), 66.4, 51.8.

(*E*)-*N*-(4-chlorobenzylidene)morpholin-4-amine (**1e**).^{8a} Afforded **1e** (426 mg, 95%) as a white solid, m.p. 94-95 °C. ^1H NMR (500 MHz, CDCl_3) δ 7.56 – 7.46 (m, 3H), 7.30 (d, J = 8.5 Hz, 2H), 3.86 (t, J = 5.0 Hz, 4H), 3.15 (t, J = 5.0 Hz, 4H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 134.5, 134.4, 133.8, 128.6, 127.2, 66.3, 51.6.

(*E*)-*N*-(4-bromobenzylidene)morpholin-4-amine (**1f**).^{8b} Afforded **1f** (472 mg, 88%) as a white solid, m.p. 128-129 °C. ^1H NMR (500 MHz, CDCl_3): δ 7.50 (s, 1H), 7.47 -7.44 (m, 4H), 3.88 (t, J = 5.0 Hz, 4H), 3.17 (t, J = 5.0 Hz, 4H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 134.9, 134.5, 131.6, 127.6, 122.4, 66.4, 51.7.

(*E*)-1-(4-((morpholinoimino)methyl)phenyl)ethanone (**1g**). Afforded **1g** (418 mg, 90%) as a yellow solid, m.p. 97-98 °C. ^1H NMR (500 MHz, CDCl_3): δ 7.92 (d, J = 8.4 Hz, 2H), 7.65 (d, J = 8.4 Hz, 2H), 7.55 (s, 1H), 3.88 (t, J = 5.0 Hz, 4H), 3.22 (t, J = 5.0 Hz, 4H), 2.58 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 197.5, 140.5, 136.3, 133.6, 128.7, 125.9, 66.3, 51.4,

1
2
3
4 26.6. HRMS: m/z (EI-TOF) calculated [M]: 232.1212, found: 232.1208.

5
6 (*E*)-4-((morpholinoimino)methyl)benzonitrile (**1h**).¹⁹ Afforded **1h** (357 mg, 83%) as a
7
8 white solid, m.p. 124-125 °C. ¹H NMR (500 MHz, CDCl₃): δ 7.66 (d, J = 8.4 Hz, 2H), 7.60 (d,
9
10 J = 8.4 Hz, 2H), 7.49 (s, 1H), 3.88 (t, J = 5.0 Hz, 4H), 3.22 (t, J = 5.0 Hz, 4H). ¹³C{¹H}NMR
11
12 (125 MHz, CDCl₃): δ 140.4, 132.4, 132.3, 126.2, 119.0, 110.8, 66.2, 51.3.

13
14
15
16 (*E*)-N-(4-nitrobenzylidene)morpholin-4-amine (**1i**).^{9a} Afforded **1i** (423 mg, 90%) as a
17
18 yellow solid, m.p. 145-146 °C. ¹H NMR (500 MHz, CDCl₃): δ 8.15 (d, J = 8.8 Hz, 2H), 7.68
19
20 (d, J = 8.8 Hz, 2H), 7.50 (s, 1H), 3.87 (t, J = 5.0 Hz, 4H), 3.24 (t, J = 5.0 Hz, 4H).
21
22 ¹³C{¹H}NMR (125 MHz, CDCl₃): δ 146.8, 142.4, 131.4, 126.1, 123.8, 66.1, 51.1.

23
24
25
26 (*E*)-N-(4-(trifluoromethyl)benzylidene)morpholin-4-amine (**1j**).^{8a} Afforded **1j** (475 mg,
27
28 92%) as a white solid, m.p. 75-76 °C. ¹H NMR (500 MHz, CDCl₃): δ 7.68 (d, J = 8.2 Hz, 2H),
29
30 7.58 (d, J = 8.3 Hz, 2H), 7.55 (s, 1H), 3.89 (t, J = 5.0 Hz, 4H), 3.21 (t, J = 5.0 Hz, 4H).
31
32 ¹³C{¹H}NMR (125 MHz, CDCl₃): δ 139.4, 133.5, 129.7 (t, J = 31.3 Hz), 125.1, 125.4 (t, J =
33
34 3.8 Hz), 124.2 (t, J = 270 Hz), 66.3, 51.5.

35
36
37
38 (*E*)-N-(4-(dimethylamino)benzylidene)morpholin-4-amine (**1k**).²⁰ Afforded **1k** (419 mg,
39
40 90%) as a pale yellow solid, m.p. 154-155 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.61 (s, 1H),
41
42 7.50 (d, J = 8.8 Hz, 2H), 6.69 (d, J = 8.9 Hz, 2H), 3.88 (t, J = 5.0 Hz, 4H), 3.11(t, J = 5.0 Hz,
43
44 4H), 2.98 (s, 6H). ¹³C{¹H}NMR (125 MHz, CDCl₃): δ 150.7, 138.7, 127.5, 124.1, 112.0, 66.5,
45
46 52.5, 40.3.

47
48
49
50
51 (*E*)-N-(3,4-dimethoxybenzylidene)morpholin-4-amine (**1l**).²¹ Afforded **1l** (490 mg, 95%)
52
53 as a white solid, m.p. 68-69 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.56 (s, 1H), 7.31 (d, J = 1.8
54
55 Hz, 1H), 6.99 (dd, J = 8.2, 1.8 Hz, 1H), 6.82 (d, J = 8.2 Hz, 1H), 3.91 (s, 3H), 3.88 (s, 3H),
56
57
58
59
60

1
2
3
4 3.87 (t, $J = 5.0$ Hz, 4H), 3.14 (t, $J = 5.0$ Hz, 4H). $^{13}\text{C}\{1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 149.5,
5
6 149.1, 136.7, 128.9, 120.4, 110.5, 107.2, 66.4, 55.8, 55.7, 52.0.
7

8
9 (*E*)-2-methoxy-4-((morpholinoimino)methyl)phenol (**1m**).²⁰ Afforded **1m** (420 mg, 89%)
10
11 as a brown solid, m.p. 152-153 °C. ^1H NMR (500 MHz, CDCl_3): δ 7.56 (s, 1H), 7.30 (d, $J =$
12
13 1.5 Hz, 1H), 6.96 (dd, $J = 8.1, 1.4$ Hz, 1H), 6.88 (d, $J = 8.1$ Hz, 1H), 3.91 (s, 3H), 3.88 (t, $J =$
14
15 5.0 Hz, 4H), 3.14 (t, $J = 5.0$ Hz, 4H). $^{13}\text{C}\{1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 146.9, 146.4, 137.2,
16
17 128.5, 121.2, 114.1, 107.0, 66.5, 55.8, 52.1.
18
19

20
21 (*E*)-*N*-(3-chlorobenzylidene)morpholin-4-amine (**1n**).^{8a} Afforded **1n** (430 mg, 96%) as a
22
23 white solid, m.p. 43-44 °C. ^1H NMR (500 MHz, CDCl_3) δ 7.62 (t, $J = 1.6$ Hz, 1H), 7.48 (s,
24
25 1H), 7.42 (dt, $J = 7.4, 1.4$ Hz, 1H), 7.26 (t, $J = 7.6$ Hz, 1H), 7.25 – 7.21 (m, 1H), 3.88 (t, $J =$
26
27 5.0 Hz, 4H), 3.18 (t, $J = 5.0$ Hz, 4H). $^{13}\text{C}\{1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 137.9, 134.6, 133.9,
28
29 129.7, 128.0, 125.7, 124.4, 66.3, 51.6.
30
31
32

33
34 (*E*)-*N*-(3-nitrobenzylidene)morpholin-4-amine (**1o**).²² Afforded **1o** (428 mg, 91%) as a
35
36 yellow solid, m.p. 145-146 °C. ^1H NMR (500 MHz, CDCl_3) δ 8.41 (s, 1H), 8.07 (dd, $J = 8.1,$
37
38 2.3 Hz, 1H), 7.88 (d, $J = 7.7$ Hz, 1H), 7.54 (s, 1H), 7.48 (t, $J = 8.0$ Hz, 1H), 3.88 (t, $J = 5.0$ Hz,
39
40 4H), 3.22 (t, $J = 5.0$ Hz, 4H). $^{13}\text{C}\{1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 148.6, 138.0, 132.0, 131.4,
41
42 129.3, 122.3, 120.6, 66.3, 51.4.
43
44
45

46
47 (*E*)-*N*-(2-methylbenzylidene)morpholin-4-amine (**1p**).^{8b} Afforded **1p** (384 mg, 94%) as a
48
49 brown solid, m.p. 64-65 °C. ^1H NMR (500 MHz, CDCl_3) δ 7.82 (s, 1H), 7.81 – 7.77 (m, 1H),
50
51 7.21 – 7.18 (m, 2H), 7.17 – 7.12 (m, 1H), 3.91 (t, $J = 5.0$ Hz, 4H), 3.19 (t, $J = 5.0$ Hz, 4H),
52
53 2.43 (s, 3H). $^{13}\text{C}\{1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 135.4, 134.9, 133.7, 130.5, 128.1, 126.1,
54
55 125.5, 66.4, 51.9, 19.5.
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(*E*)-*N*-(2-methoxybenzylidene)morpholin-4-amine (**1q**).^{8a} Afforded **1q** (722 mg, 96%) as a pale yellow solid, m.p. 76-77 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.99 (s, 1H), 7.87 (dd, *J* = 7.7, 1.7 Hz, 1H), 7.26 (dt, *J* = 7.5, 5.0 Hz, 1H), 6.95 (t, *J* = 7.5 Hz, 1H), 6.88 (d, *J* = 8.3 Hz, 1H), 3.89 (t, *J* = 5.0 Hz, 4H), 3.85 (s, 3H), 3.18 (t, *J* = 5.0 Hz, 4H). ¹³C{¹H}NMR (125 MHz, CDCl₃): δ 157.0, 132.3, 129.4, 125.4, 124.4, 120.8, 110.7, 66.4, 55.4, 52.0.

(*E*)-*N*-(2-bromobenzylidene)morpholin-4-amine (**1r**). Afforded **1r** (509 mg, 95%) as a white solid, m.p. 77-78 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.92 (dd, *J* = 7.9, 1.7 Hz, 1H), 7.87 (s, 1H), 7.52 (dd, *J* = 8.0, 1.1 Hz, 1H), 7.28 (t, *J* = 5.0 Hz, 1H), 7.12 (td, *J* = 7.9, 1.7 Hz, 1H), 3.89 (t, *J* = 5.0 Hz, 4H), 3.22 (t, *J* = 5.0 Hz, 4H). ¹³C{¹H}NMR (125 MHz, CDCl₃): δ 134.6, 34.6, 132.8, 129.3, 127.4, 126.7, 123.2, 66.3, 51.7. HRMS: *m/z* (EI-TOF) calculated [M]: 268.0211, found: 268.0203.

(*E*)-*N*-(naphthalen-2-ylmethylene)morpholin-4-amine (**1s**).¹⁸ Afforded **1s** (432 mg, 92%) as a white solid, m.p. 125-127 °C. ¹H NMR (500 MHz, CDCl₃): δ 7.95 (dd, *J* = 8.6, 1.4 Hz, 1H), 7.86 (s, 1H), 7.85 – 7.80 (m, 3H), 7.75 (s, 1H), 7.46- 7.45 (m, 2H), 3.92 (t, *J* = 5.0 Hz, 4H), 3.24 (t, *J* = 5.0 Hz, 4H). ¹³C{¹H}NMR (125 MHz, CDCl₃): δ 136.2, 133.7, 133.5, 133.4, 128.3, 128.0, 127.8, 126.6, 126.2, 126.0, 123.0, 66.4, 51.8

(*E*)-*N*-(pyridin-3-ylmethylene)morpholin-4-amine (**1t**). Afforded **1t** (330 mg, 86%) as a brown solid, m.p. 31-32 °C. ¹H NMR (500 MHz, CDCl₃): δ 8.70 (d, *J* = 1.8 Hz, 1H), 8.47 (dd, *J* = 4.8, 1.6 Hz, 1H), 7.96 (dt, *J* = 8.0, 1.8 Hz, 1H), 7.52 (s, 1H), 7.25 (dd, *J* = 7.9, 4.8 Hz, 1H), 3.87 (t, *J* = 5.0 Hz, 4H), 3.19 (t, *J* = 5.0 Hz, 4H). ¹³C{¹H}NMR (125 MHz, CDCl₃): δ 149.0, 148.2, 132.3, 131.9, 131.8, 123.5, 66.3, 51.5. HRMS: *m/z* (EI-TOF) calculated [M]: 191.1059, found: 191.1057.

1
2
3
4 (E)-N-(thiophen-2-ylmethylene)morpholin-4-amine (**1u**).²³ Afforded **1u** (345 mg, 88%) as
5
6 a brown solid, m.p. 92-93 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.76 (s, 1H), 7.2 (d, *J* = 5.0 Hz,
7
8 1H), 7.07 (dd, *J* = 3.6, 0.8 Hz, 1H), 6.99 (dd, *J* = 5.1, 3.6 Hz, 1H), 3.86 (t, *J* = 5.0 Hz, 4H),
9
10 3.13 (t, *J* = 5.0 Hz, 4H). ¹³C{¹H}NMR (125 MHz, CDCl₃): δ 141.5, 131.2, 127.1, 126.3, 125.5,
11
12 66.3, 51.8.
13
14

15
16 (E)-N-(furan-2-ylmethylene)morpholin-4-amine (**1v**). Afforded **1v** (299 mg, 83%) as a
17
18 pale yellow solid, m.p. 53-54 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.45 (s, 1H), 7.41 (d, *J* = 0.8
19
20 Hz, 1H), 6.46 (d, *J* = 3.4 Hz, 1H), 6.43 – 6.38 (m, 1H), 3.85 (t, *J* = 5.0 Hz, 4H), 3.13 (t, *J* =
21
22 5.0 Hz, 4H). ¹³C{¹H}NMR (125 MHz, CDCl₃): δ 151.1, 142.7, 126.6, 111.3, 109.2, 66.2, 51.6.
23
24 HRMS: *m/z* (EI-TOF) calculated [M]: 180.0899, found: 180.0894.
25
26
27

28
29 (E)-N-(benzo[b]thiophen-3-ylmethylene)morpholin-4-amine (**1w**). Afforded **1w** (423 mg,
30
31 86%) as a brown solid, m.p. 73-74 °C. ¹H NMR (500 MHz, CDCl₃): δ 8.67 (dd, *J* = 7.4, 0.7
32
33 Hz, 1H), 7.93 (s, 1H), 7.87 – 7.83 (m, 1H), 7.51 (s, 1H), 7.41 (dtd, *J* = 14.9, 7.2, 1.2 Hz, 2H),
34
35 3.92 (t, *J* = 5.0 Hz, 4H), 3.22 (t, *J* = 5.0 Hz, 4H). ¹³C{¹H}NMR (125 MHz, CDCl₃): δ 140.7,
36
37 136.3, 132.7, 132.4, 126.6, 124.9, 124.9, 124.6, 122.5, 66.4, 51.8. HRMS: *m/z* (EI-TOF)
38
39 calculated [M]: 342.0827, found: 246.0826.
40
41
42

43
44 (E)-N-((1H-indol-3-yl)methylene)morpholin-4-amine (**1x**).²⁴ Afforded **1x** (357 mg, 78%)
45
46 as a pale white solid, m.p. 128-129 °C. ¹H NMR (500 MHz, CDCl₃) δ 8.52 (s, 1H), 8.32 (d, *J*
47
48 = 7.4 Hz, 1H), 7.99 (s, 1H), 7.34 (dd, *J* = 7.1, 1.1 Hz, 1H), 7.30 (d, *J* = 2.6 Hz, 1H), 7.25 –
49
50 7.23 (m, 1H), 7.22 – 7.17 (m, 1H), 3.93 (t, *J* = 5.0 Hz, 4H), 3.18 (t, *J* = 5.0 Hz, 4H).
51
52 ¹³C{¹H}NMR (125 MHz, CDCl₃): δ 136.7, 135.2, 125.5, 124.8, 123.0, 122.0, 120.7, 114.0,
53
54 111.1, 66.5, 52.6.
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(*E*)-*N*-(3-phenylpropylidene)morpholin-4-amine (**1y**).^{8a} Afforded **1y** (392 mg, 90%) as a clear colorless liquid. ¹H NMR (500 MHz, CDCl₃) δ 7.29 (dd, *J* = 10.1, 4.9 Hz, 2H), 7.24 – 7.17 (m, 3H), 6.97 (t, *J* = 5.3 Hz, 1H), 3.82 (t, *J* = 5.0 Hz, 4H), 2.94 (t, *J* = 5.0 Hz, 4H), 2.83 (t, *J* = 7.5 Hz, 2H), 2.62 – 2.54 (m, 2H). ¹³C{¹H}NMR (125 MHz, CDCl₃): δ 141.1, 140.6, 128.4, 128.3, 126.0, 66.4, 52.3, 34.6, 33.6.

(*E*)-ethyl 3-(2,2-dimethylhydrazono)-2,2-difluoro-5-phenylpentanoate (**1z**).^{9a} Afforded **1z** (290mg, 48%) as a pale yellow liquid. ¹H NMR (500 MHz, CDCl₃) δ 7.31 – 7.27 (m, 2H), 7.24 – 7.20 (m, 3H), 6.67 (t, *J* = 5.4 Hz, 1H), 2.84 – 2.79 (m, 2H), 2.73 (s, 6H), 2.60 – 2.52 (m, 2H). ¹³C{¹H}NMR (125 MHz, CDCl₃): δ 141.4, 138.0, 128.4, 128.3, 125.9, 43.3, 34.7, 34.1

(*E*)-*N*-octylidenemorpholin-4-amine (**1aa**).²⁵ Afforded **1aa** (352mg, 83%) as a clear colorless liquid. ¹H NMR (500 MHz, CDCl₃) δ 6.95 (t, *J* = 5.6 Hz, 1H), 3.80 (t, *J* = 5.0 Hz, 4H), 2.92 (t, *J* = 5.0 Hz, 4H), 2.25 – 2.19 (m, 2H), 1.46 (dt, *J* = 15.1, 7.4 Hz, 2H), 1.31 – 1.23 (m, 8H), 0.85 (t, *J* = 6.9 Hz, 3H). ¹³C{¹H}NMR (125 MHz, CDCl₃): δ 142.4, 67.0, 66.4, 52.5, 33.0, 31.7, 29.1, 29.0, 27.4, 22.6, 14.0.

(*E*)-*N*-hexylidenemorpholin-4-amine (**1ab**). Afforded **1ab** (302 mg, 82%) as a clear colorless liquid. ¹H NMR (500 MHz, CDCl₃) δ 6.96 (t, *J* = 5.6 Hz, 1H), 3.80 (t, *J* = 5.0 Hz, 4H), 2.92 (t, *J* = 5.0 Hz, 4H), 2.26 – 2.18 (m, 2H), 1.52 – 1.40 (m, 2H), 1.33 – 1.26 (m, 4H), 0.87 (t, *J* = 7.5 Hz, 3H). ¹³C{¹H}NMR (125 MHz, CDCl₃): δ 142.4, 66.4, 52.5, 33.0, 31.3, 27.0, 22.4, 13.9. HRMS: *m/z* (EI-TOF) calculated [M]: 184.1576, found: 184.1570.

(*E*)-*N*-pentylidenemorpholin-4-amine (**1ac**). Afforded **1ac** (296 mg, 87%) as a clear colorless liquid. ¹H NMR (500 MHz, CDCl₃) δ 6.95 (t, *J* = 5.6 Hz, 1H), 3.80 (t, *J* = 5.0 Hz,

1
2
3
4 4H), 2.92 (t, $J = 5.0$ Hz, 4H), 2.27 – 2.18 (m, 2H), 1.48 – 1.40 (m, 2H), 1.38 – 1.29 (m, 2H),
5
6 0.89 (t, $J = 7.3$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 142.4, 66.4, 52.4, 32.7, 29.5,
7
8 22.2, 13.9. HRMS: m/z (EI-TOF) calculated [M]: 170.1419, found:170.1415.

9
10
11 (*E*)-1-(4-methylbenzylidene)-2-phenylhydrazine (**1ad**).²⁶ Afforded **1ad** (412 mg, 98%) as
12
13 a brown solid, m.p. 108-109 °C. ^1H NMR (500 MHz, CDCl_3): δ 7.63 (s, 1H), 7.57 (d, $J = 8.1$
14
15 Hz, 2H), 7.53 (s, 1H), 7.33 – 7.27 (m, 2H), 7.20 (d, $J = 8.0$ Hz, 2H), 7.12 (dd, $J = 8.5, 0.9$ Hz,
16
17 2H), 6.92 – 6.85 (m, 1H), 2.39 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 144.8, 138.4,
18
19 137.5, 132.5, 129.3, 129.2, 126.1, 119.9, 112.7, 21.4.
20
21
22

23
24 (*E*)-N-(4-bromobenzylidene)piperidin-1-amine (**1ae**). Afforded **1ae** (495 mg, 93%) as a
25
26 white solid, m.p. 51-52 °C. ^1H NMR (500 MHz, CDCl_3) δ 7.54 – 7.37 (m, 5H), 3.16 (t, $J = 5.0$
27
28 Hz, 4H), 1.74 (dt, $J = 11.6, 5.8$ Hz, 4H), 1.57 – 1.52 (m, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz,
29
30 CDCl_3): δ 135.7, 132.7, 131.5, 127.3, 121.3, 51.9, 25.1, 24.1. HRMS: m/z (EI-TOF)
31
32 calculated [M]: 266.0419, found:266.0417.
33
34
35

36
37 (*E*)-N-(4-bromobenzylidene)-4-methylpiperazin-1-amine (**1af**). Afforded **1af** (489 mg,
38
39 87%) as a white solid, m.p.140-141 °C. ^1H NMR (500 MHz, CDCl_3) δ 7.49 -7.45 (m, 5H),
40
41 3.20 (t, $J = 5.0$ Hz, 4H), 2.60 (t, $J = 5.0$ Hz, 4H), 2.35 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz,
42
43 CDCl_3): δ 135.2, 134.0, 131.5, 127.4, 121.7, 54.4, 50.8, 45.9. HRMS: m/z (EI-TOF)
44
45 calculated [M]: 281.0528, found: 281.0525.
46
47
48

49 (*E*)-4-methylbenzaldehyde oxime (**1ag**).²⁷ Afforded **1ag** (182 mg, 75%) as a white solid,
50
51 m.p. 70-71 °C. ^1H NMR (500 MHz, CDCl_3) δ 9.24 (s, 1H), 8.17 (s, 1H), 7.49 (d, $J = 8.1$ Hz,
52
53 2H), 7.21 (d, $J = 8.0$ Hz, 2H), 2.38 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 150.3, 140.3,
54
55 129.5, 129.0, 127.0, 21.4.
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(*E*)-*N'*-(4-methylbenzylidene)benzenesulfonylhydrazide (**1ah**).^{8a} Afforded **1ah** (507 mg, 88%) as a white solid, m.p. 116-117 °C. ¹H NMR (500 MHz, CDCl₃): δ 8.44 (s, 1H), 8.02 (s, 1H), 8.00 (d, *J* = 1.4 Hz, 1H), 7.77 (s, 1H), 7.61 – 7.55 (m, 1H), 7.50 (dd, *J* = 10.5, 4.7 Hz, 2H), 7.46 (d, *J* = 8.1 Hz, 2H), 7.14 (d, *J* = 8.0 Hz, 2H), 2.34 (s, 3H). ¹³C{¹H}NMR (125 MHz, CDCl₃): δ 148.4, 140.8, 138.1, 133.2, 130.3, 129.3, 129.0, 127.8, 127.3, 21.4.

2-Bromo-2,2-difluoro-*N*-phenylacetamide (**2b**).^{9d} Afforded **2b** (488 mg, 98%) as a white solid, m.p. 83-84 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.95 (s, 1H), 7.57 (d, *J* = 8.2 Hz, 2H), 7.39 (t, *J* = 7.8 Hz, 2H), 7.24 (t, *J* = 7.4 Hz, 1H). ¹³C{¹H}NMR (125 MHz, CDCl₃): δ 157.5 (t, *J* = 27.5 Hz), 135.3, 129.4, 126.24, 114.00, 111.5 (t, *J* = 315.0 Hz). ¹⁹F NMR (471 MHz, CDCl₃): δ -60.6.

(*E*)-ethyl 2,2-difluoro-3-(morpholinoimino)-3-(*p*-tolyl)propanoate (**3**).^{8a} The procedure was operated in general method. The reaction gave 63 mg of (*E*)-ethyl 2,2-difluoro-3-(morpholinoimino)-3-(*p*-tolyl)propanoate in 96 % isolated yield as a pale yellow solid (PE/EA=10:1), m.p. 68-69°C. ¹H NMR (500 MHz, CDCl₃) δ 7.37 (d, *J* = 8.0 Hz, 2H), 7.21 (d, *J* = 8.0 Hz, 2H), 4.37 (q, *J* = 7.1 Hz, 2H), 3.60 (t, *J* = 5.0 Hz, 4H), 2.93 (t, *J* = 5.0 Hz, 4H), 2.37 (s, 3H), 1.37 (t, *J* = 7.1 Hz, 3H). ¹³C{¹H}NMR (125 MHz, CDCl₃): δ 163.7 (t, *J* = 31.3 Hz), 141.1 (t, *J* = 31.3 Hz), 139.7, 129.4, 128.5, 128.2, 114.32 (t, *J* = 248.6 Hz), 65.98, 62.5, 54.1, 21.4, 14.0. ¹⁹F NMR (471 MHz, CDCl₃): δ -101.54.

(*E*)-ethyl 2,2-difluoro-3-(morpholinoimino)-3-phenylpropanoate (**4**).^{8a} The procedure was operated in general method. The reaction gave 79 mg of (*E*)-ethyl 2,2-difluoro-3-(morpholinoimino)-3-phenylpropanoate in 87 % isolated yield as a clear yellow liquid (PE/EA=10:1). ¹H NMR (500 MHz, CDCl₃) δ 7.47 (dd, *J* = 6.1, 2.6 Hz, 2H),

1
2
3
4 7.43 – 7.38 (m, 3H), 4.37 (q, $J = 7.1$ Hz, 2H), 3.58 (t, $J = 5.0$ Hz, 4H), 2.92 (t, $J = 5.0$ Hz, 4H),
5
6 1.37 (t, $J = 7.1$ Hz, 3H). $^{13}\text{C}\{1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 163.64(t, $J = 31.3$ Hz), 140.63 (t,
7
8 $J = 30.0$ Hz), 131.2, 129.7, 128.6, 128.6, 114.3 (t, $J = 247.5$ Hz), 65.9, 62.5, 54.1, 14.0. ^{19}F
9
10 NMR (471 MHz, CDCl_3): δ -101.49.

11
12
13 (*E*)-ethyl 2,2-difluoro-3-(4-methoxyphenyl)-3-(morpholinoimino)propanoate (**5**). The
14
15 procedure was operated in general method. The reaction gave 99 mg of (*E*)-ethyl
16
17 2,2-difluoro-3-(4-methoxyphenyl)-3-(morpholinoimino) propanoate in 97 % isolated yield as
18
19 a pale yellow liquid (PE/EA=5:1). ^1H NMR (500 MHz, CDCl_3): δ 7.44 (d, $J = 8.8$ Hz, 2H),
20
21 6.92 (d, $J = 8.9$ Hz, 2H), 4.36 (q, $J = 7.1$ Hz, 2H), 3.82 (s, 3H), 3.60 (t, $J = 5.0$ Hz, 4H), 2.92
22
23 (t, $J = 5.0$ Hz, 4H), 1.37 (t, $J = 7.1$ Hz, 3H). $^{13}\text{C}\{1\text{H}\}$ NMR (125 MHz, CDCl_3) δ 163.7 (t, $J =$
24
25 31.3Hz), 160.46, 141.5 (t, $J = 31.3$ Hz), 129.9, 123.0, 116.33, 114.35 (t, $J = 247.5$ Hz), 114.1,
26
27 66.0, 62.5, 55.2, 54.0, 14.0. ^{19}F NMR (471 MHz, CDCl_3) δ -101.52. HRMS: m/z (EI-TOF)
28
29 calculated [M]: 342.1391, found: 342.1388.

30
31
32 (*E*)-ethyl 2,2-difluoro-3-(4-fluorophenyl)-3-(morpholinoimino)propanoate (**6**).^{8a} The
33
34 procedure was operated in general method. The reaction gave 84 mg of (*E*)-ethyl
35
36 2,2-difluoro-3-(4-fluorophenyl)-3-(morpholinoimino) propanoate in 85 % isolated yield as a
37
38 clear colorless liquid (PE/EA=10:1). ^1H NMR (500 MHz, CDCl_3) δ 7.48 (dd, $J = 8.6, 5.4$ Hz,
39
40 2H), 7.11 (t, $J = 8.7$ Hz, 2H), 4.37 (q, $J = 7.1$ Hz, 2H), 3.60 (t, $J = 5.0$ Hz, 4H), 2.91 (t, $J = 5.0$
41
42 Hz, 4H), 1.37 (t, $J = 7.1$ Hz, 3H). $^{13}\text{C}\{1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 163.45 (t, $J = 31.3$ Hz),
43
44 163.2 (d, $J = 248.8$ Hz), 140.0 (t, $J = 31.3$ Hz), 130.7 (t, $J = 7.5$ Hz), 127.1 (t, $J = 2.5$ Hz)
45
46 115.9 (t, $J = 21.3$ Hz), 114.2 (t, $J = 247.5$ Hz), 65.9, 62.6, 54.1, 14.0. ^{19}F NMR (471 MHz,
47
48 CDCl_3): δ -101.5, -109.8

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(*E*)-ethyl 3-(4-chlorophenyl)-2,2-difluoro-3-(morpholinoimino)propanoate (**7**).^{8a} The procedure was operated in general method. The reaction gave 86 mg of (*E*)-ethyl 2,2-difluoro-3-(4-chlorophenyl)-3-(morpholinoimino) propanoate in 83 % isolated yield as a pale yellow liquid (PE/EA=10:1). ¹H NMR (500 MHz, CDCl₃) δ 7.46 – 7.36 (m, 4H), 4.37 (q, *J* = 7.1 Hz, 2H), 3.60 (t, *J* = 5.0 Hz, 4H), 2.93 (t, *J* = 5.0 Hz, 4H), 1.37 (t, *J* = 7.1 Hz, 3H). ¹³C{¹H}NMR (125 MHz, CDCl₃): δ 163.64, 163.38 (t, *J* = 32.5 Hz), 139.46 (t, *J* = 31.3 Hz), 135.9, 130.09, 129.59, 129.09, 114.1 (t, *J* = 247.5 Hz), 65.9, 62.6, 54.1, 14.0. ¹⁹F NMR (471 MHz, CDCl₃): δ -101.3.

(*E*)-ethyl 3-(4-bromophenyl)-2,2-difluoro-3-(morpholinoimino)propanoate (**8**). The procedure was operated in general method. The reaction gave 95 mg of (*E*)-ethyl 2,2-difluoro-3-(4-bromophenyl)-3-(morpholinoimino) propanoate in 81 % isolated yield as a pale yellow liquid (PE/EA=10:1). ¹H NMR (500 MHz, CDCl₃) δ 7.55 (d, *J* = 8.5 Hz, 2H), 7.36 (d, *J* = 8.5 Hz, 2H), 4.37 (q, *J* = 7.1 Hz, 2H), 3.60 (t, *J* = 5.0 Hz, 4H), 2.93 (t, *J* = 5.0 Hz, 4H), 1.37 (t, *J* = 7.1 Hz, 3H). ¹³C{¹H}NMR (125 MHz, CDCl₃): δ 163.36 (t, *J* = 31.3 Hz), 139.35 (t, *J* = 32.5 Hz), 132.0, 130.2, 130.0, 124.2, 114.1 (t, *J* = 251.3 Hz), 65.9, 62.6, 54.1, 14.0. ¹⁹F NMR (471 MHz, CDCl₃): δ -101.3. HRMS: *m/z* (EI-TOF) calculated [M]: 390.0391, found: 390.0386.

(*E*)-ethyl 3-(4-acetylphenyl)-2,2-difluoro-3-(morpholinoimino)propanoate (**9**). The procedure was operated in general method. The reaction gave 86 mg of (*E*)-ethyl 2,2-difluoro-3-(4-acetylphenyl)-3-(morpholinoimino) propanoate in 83 % isolated yield as a yellow liquid (PE/EA=5:1). ¹H NMR (500 MHz, CDCl₃): δ 7.98 (d, *J* = 8.3 Hz, 2H), 7.58 (d, *J* = 8.2 Hz, 2H), 4.37 (q, *J* = 7.1 Hz, 2H), 3.58 (t, *J* = 5.0 Hz, 4H), 2.92 (t, *J* = 5.0 Hz, 4H),

1
2
3
4 2.61 (s, 3H), 1.37 (t, $J = 7.1$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 197.2, 163.30 (t, J
5
6 = 31.3 Hz), 138.8 (t, $J = 31.3$ Hz), 137.7, 136.0, 129.0, 128.4, 114.08 (t, $J = 248.8$ Hz), 65.8,
7
8 62.7, 54.2, 26.6, 14.0. ^{19}F NMR (471 MHz, CDCl_3): δ -101.1. HRMS: m/z (EI-TOF)
9
10 calculated [M]: 354.1391, found: 354.1385.

11
12
13
14 (*E*)-ethyl 3-(4-cyanophenyl)-2,2-difluoro-3-(morpholinoimino)propanoate (**10**). The
15
16 procedure was operated in general method. The reaction gave 75 mg of (*E*)-ethyl
17
18 2,2-difluoro-3-(4-acetylphenyl)-3-(morpholinoimino) propanoate in 74 % isolated yield as a
19
20 yellow solid (PE/EA=10:1). ^1H NMR (500 MHz, CDCl_3): δ 7.72 (d, $J = 8.5$ Hz, 2H), 7.60 (d,
21
22 $J = 8.4$ Hz, 2H), 4.38 (q, $J = 7.1$ Hz, 2H), 3.60 (t, $J = 5.0$ Hz, 4H), 3.92 (t, $J = 5.0$ Hz, 4H),
23
24 1.37 (t, $J = 7.1$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 163.0 (t, $J = 31.3$ Hz), 137.7 (t, J
25
26 = 31.3 Hz), 136.0, 132.3, 129.5, 117.9, 114.0 (t, $J = 31.3$ Hz), 113.6, 65.8, 62.8, 54.3, 14.0. ^{19}F
27
28 NMR (471 MHz, CDCl_3): δ -100.8. HRMS: m/z (EI-TOF) calculated [M]: 377.1238, found:
29
30 337.1240.
31
32
33
34
35

36
37 (*E*)-ethyl 2,2-difluoro-3-(morpholinoimino)-3-(4-nitrophenyl)propanoate (**11**).^{9d} The
38
39 procedure was operated in general method. The reaction gave 91 mg of (*E*)-ethyl
40
41 2,2-difluoro-3-(morpholinoimino)-3-(4-nitrophenyl) propanoate in 85 % isolated yield as a
42
43 yellow solid (PE/EA=10:1), m.p. 119-120 °C. ^1H NMR (500 MHz, CDCl_3) δ 8.28 (d, $J = 8.8$
44
45 Hz, 2H), 7.68 (d, $J = 8.7$ Hz, 2H), 4.38 (q, $J = 7.1$ Hz, 2H), 3.60 (t, $J = 5.0$ Hz, 4H), 2.94 (t, J
46
47 = 5.0 Hz, 4H), 1.38 (t, $J = 7.1$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 163.0 (t, $J =$
48
49 30.0Hz), 148.3, 137.9, 137.2 (t, $J = 32.5$ Hz), 129.9, 123.8, 113.93 (t, $J = 248.8$ Hz), 65.8, 62.8,
50
51 54.3, 14.0. ^{19}F NMR (471 MHz, CDCl_3): δ -100.7.
52
53
54
55

56
57 (*E*)-ethyl 2,2-difluoro-3-(morpholinoimino)-3-(4-(trifluoromethyl)phenyl)propanoate
58
59
60

1
2
3
4 (12).^{8a} The procedure was operated in general method. The reaction gave 92 mg of (*E*)-ethyl
5
6 2,2-difluoro-3-(morpholinoimino)-3-(4-trifluoromethylphenyl) propanoate in 80% isolated
7
8 yield as a yellow solid (PE/EA=10:1), m.p. 78-79 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.68 (d,
9
10 *J* = 8.2 Hz, 2H), 7.61 (d, *J* = 8.1 Hz, 2H), 4.38 (q, *J* = 7.1 Hz, 2H), 3.60 (t, *J* = 5.0 Hz, 4H),
11
12 2.93 (t, *J* = 5.0 Hz, 4H), 1.38 (t, *J* = 7.1 Hz, 3H). ¹³C{¹H}NMR (125 MHz, CDCl₃): δ 163.3 (t,
13
14 *J* = 31.3 Hz), 138.5 (t, *J* = 31.3 Hz), 135.0, 131.7 (q, *J* = 32.5 Hz), 129.2, 125.6 (q, *J* = 3.8
15
16 Hz), 123.6 (q, *J* = 271.3 Hz), 114.1 (t, *J* = 248.8 Hz), 65.9, 62.7, 54.2, 14.0. ¹⁹F NMR (471
17
18 MHz, CDCl₃): δ -63.0, -101.1.

19
20
21
22
23
24 (*E*)-ethyl 3-(4-(dimethylamino)phenyl)-2,2-difluoro-3-(morpholinoimino)propanoate (13).
25
26 The procedure was operated in general method. The reaction gave 65 mg of (*E*)-ethyl
27
28 3-(4-(dimethylamino)phenyl)-2,2-difluoro-3-(morpholinoimino)propanoate in 61 % isolated
29
30 yield as a clear colorless liquid (PE/EA=1:1). ¹H NMR (500 MHz, CDCl₃) δ 7.45 (d, *J* = 8.8
31
32 Hz, 2H), 6.68 (d, *J* = 9.0 Hz, 2H), 4.36 (q, *J* = 7.1 Hz, 2H), 3.63 (t, *J* = 5.0 Hz, 4H), 3.00 (s,
33
34 6H), 2.94 (t, *J* = 5.0 Hz, 4H), 1.37 (t, *J* = 7.1 Hz, 3H). ¹³C{¹H}NMR (125 MHz, CDCl₃): δ
35
36 163.95 (t, *J* = 31.9 Hz), 150.9, 143.38 (t, *J* = 30.0 Hz), 129.4, 117.4, 114.67 (t, *J* = 248.8 Hz),
37
38 111.40, 66.1, 62.4, 54.0, 40.0, 14.0. ¹⁹F NMR (471 MHz, CDCl₃): δ -101.3. HRMS: *m/z*
39
40 (EI-TOF) calculated [M]: 355.1707, found: 355.1706.

41
42
43
44
45
46 (*E*)-ethyl 3-(3,4-dimethoxyphenyl)-2,2-difluoro-3-(morpholinoimino)propanoate (14).
47
48 The procedure was operated in general method. The reaction gave 107 mg of (*E*)-ethyl
49
50 3-(3,4-dimethoxyphenyl)-2,2-difluoro-3-(morpholinoimino)propanoate in 96 % isolated yield
51
52 as a clear colorless liquid (PE/EA=5:1). ¹H NMR (500 MHz, CDCl₃): δ 7.07 (d, *J* = 8.1 Hz,
53
54 1H), 7.03 (s, 1H), 6.88 (d, *J* = 8.3 Hz, 1H), 4.37 (q, *J* = 7.1 Hz, 2H), 3.90 (s, 3H), 3.87 (s, 3H),
55
56
57
58
59
60

1
2
3
4 3.60 (t, $J = 5.0$ Hz, 4H), 2.93 (t, $J = 5.0$ Hz, 4H), 1.37 (t, $J = 7.1$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125
5
6 MHz, CDCl_3): δ 163.7 (t, $J = 31.3$ Hz), 150.1, 148.9, 141.0 (t, $J = 31.9$ Hz), 123.0, 121.6,
7
8 114.4 (t, $J = 248.1$ Hz), 111.3, 111.0, 66.1, 62.5, 56.0, 55.8, 54.0, 14.0. ^{19}F NMR (471 MHz,
9
10 CDCl_3): δ -101.4. HRMS: m/z (EI-TOF) calculated [M]: 372.1497, found: 372.1500.

11
12
13
14 (*E*)-ethyl 2,2-difluoro-3-(4-hydroxy-3-methoxyphenyl)-3-(morpholinoimino)propanoate
15
16 (15). The procedure was operated in general method. The reaction gave 100 mg of (*E*)-ethyl
17
18 3-(4-hydroxy-3-methoxyphenyl)-2,2-difluoro-3-(morpholinoimino)propanoate in 97 %
19
20 isolated yield as a clear colorless liquid (PE/EA=3:1). ^1H NMR (500 MHz, CDCl_3): δ 7.05 –
21
22 7.00 (m, 2H), 6.93 (d, $J = 8.2$ Hz, 1H), 5.95 (s, 1H), 4.37 (q, $J = 7.1$ Hz, 2H), 3.88 (s, 3H),
23
24 3.61 (t, $J = 5.0$ Hz, 4H), 2.93 (t, $J = 5.0$ Hz, 4H), 1.37 (t, $J = 7.1$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125
25
26 MHz, CDCl_3): δ 163.7 (t, $J = 31.3\text{Hz}$), 146.9, 146.5, 141.1 (t, $J = 31.3\text{Hz}$), 122.4, 114.7, 114.4
27
28 (t, $J = 253.4\text{Hz}$), 110.7, 66.1, 62.5, 56.1, 54.0, 24.8, 14.1. ^{19}F NMR (471 MHz, CDCl_3): δ
29
30 -101.4. HRMS: m/z (EI-TOF) calculated [M]: 358.1340, found: 358.1342.

31
32
33
34
35
36 (*E*)-ethyl 3-(3-chlorophenyl)-2,2-difluoro-3-(morpholinoimino)propanoate (16).^{8a} The
37
38 procedure was operated in general method. The reaction gave 103 mg of (*E*)-ethyl
39
40 2,2-difluoro-3-(3-chlorophenyl)-3-(morpholinoimino) propanoate in 99% isolated yield as a
41
42 pale yellow liquid (PE/EA=10:1). ^1H NMR (500 MHz, CDCl_3) δ 7.48 (s, 1H), 7.41 – 7.33 (m,
43
44 3H), 4.37 (q, $J = 7.1$ Hz, 2H), 3.60 (t, $J = 5.0$ Hz, 4H), 2.94 (t, $J = 5.0$ Hz, 4H), 1.37 (t, $J = 7.1$
45
46 Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 163.3 (t, $J = 31.9\text{Hz}$), 138.5 (t, $J = 31.9\text{Hz}$),
47
48 134.7, 132.9, 129.9, 129.9, 128.7, 126.9, 114.1 (t, $J = 248.8$ Hz), 65.9, 62.6, 54.2, 14.0. ^{19}F
49
50 NMR (471 MHz, CDCl_3): δ -101.2.

51
52
53
54
55
56 (*E*)-ethyl 2,2-difluoro-3-(morpholinoimino)-3-(3-nitrophenyl)propanoate (17). The
57
58
59
60

1
2
3
4 procedure was operated in general method. The reaction gave 81 mg of (*E*)-ethyl
5
6 2,2-difluoro-3-(morpholinoimino)-3-(3-nitrophenyl) propanoate in 75 % isolated yield as a
7
8 yellow solid (PE/EA=10:1). ¹H NMR (500 MHz, CDCl₃): δ 8.38 (s, 1H), 8.28 (ddd, *J* = 8.3,
9
10 2.2, 1.0 Hz, 1H), 7.82 (d, *J* = 7.7 Hz, 1H), 7.64 (t, *J* = 8.0 Hz, 1H), 4.39 (q, *J* = 7.1 Hz, 2H),
11
12 3.61 (t, *J* = 5.0 Hz, 4H), 2.95 (t, *J* = 5.0 Hz, 4H), 1.39 (t, *J* = 7.1 Hz, 3H). ¹³C{¹H}NMR (125
13
14 MHz, CDCl₃) δ 163.0 (t, *J* = 31.9 Hz), 148.2, 137.0 (t, *J* = 31.2 Hz), 134.6, 132.8, 129.8, 124.5,
15
16 123.8, 113.9 (t, *J* = 250.0 Hz), 65.8, 62.8, 54.3, 14.0. ¹⁹F NMR (471 MHz, CDCl₃) δ -100.84(d,
17
18 *J* = 9.4 Hz). HRMS: *m/z* (EI-TOF) calculated [M]: 357.1136, found: 357.1131.
19
20
21
22
23

24 (*E*)-ethyl 2,2-difluoro-3-(morpholinoimino)-3-(*o*-tolyl)propanoate (**18**). The procedure
25
26 was operated in general method. The reaction gave 63 mg of (*E*)-ethyl
27
28 2,2-difluoro-3-(morpholinoimino)-3-(*o*-tolyl)propanoate in 64 % isolated yield as a clear
29
30 colorless liquid (PE/EA=10:1). ¹H NMR (500 MHz, CDCl₃): δ 7.34 – 7.28 (m, 2H), 7.21 (t, *J*
31
32 = 8.1 Hz, 2H), 4.38 (q, *J* = 7.1 Hz, 2H), 3.62 – 3.52 (m, 4H), 2.97 – 2.84 (m, 4H), 2.28 (s, 3H),
33
34 1.38 (t, *J* = 7.1 Hz, 3H). ¹³C{¹H}NMR (125 MHz, CDCl₃): δ 163.90 (t, *J* = 32.5 Hz), 138.8 (t,
35
36 *J* = 31.3 Hz), 138.1, 131.2, 130.0, 129.7, 128.8, 125.7, 114.4 (t, *J* = 247.5 Hz), 66.3, 62.5,
37
38 53.8, 19.7, 14.1. ¹⁹F NMR (471 MHz, CDCl₃) δ -101.0 (d, *J* = 273.2 Hz), -103.3 (d, *J* = 273.2
39
40 Hz). HRMS: *m/z* (EI-TOF) calculated [M]: 326.1442, found: 326.1441.
41
42
43
44
45

46 (*E*)-ethyl 2,2-difluoro-3-(2-methoxyphenyl)-3-(morpholinoimino)propanoate (**19**).^{8a} The
47
48 procedure was operated in general method. The reaction gave 77 mg of (*E*)-ethyl
49
50 2,2-difluoro-3-(2-methoxyphenyl)-3-(morpholinoimino) propanoate in 75 % isolated yield as
51
52 a clear colorless liquid (PE/EA=5:1). ¹H NMR (500 MHz, CDCl₃) δ 7.37 (t, *J* = 7.9 Hz, 1H),
53
54 7.24 (s, 1H), 6.96 (t, *J* = 7.5 Hz, 1H), 6.90 (d, *J* = 8.3 Hz, 1H), 4.36 (q, *J* = 7.1 Hz, 2H), 3.83
55
56
57
58
59
60

(s, 3H), 3.57 (t, $J = 5.0$ Hz, 4H), 2.97 (t, $J = 5.0$ Hz, 4H), 1.36 (t, $J = 7.1$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 164.1 (t, $J = 33.1$ Hz), 157.6, 135.0 (t, $J = 31.1$ Hz), 131.2, 130.5, 120.5, 114.2 (t, $J=248.1$ Hz), 111.12, 66.2, 62.4, 55.8, 53.4, 14.1. ^{19}F NMR (471 MHz, CDCl_3): δ -101.6, -103.2.

(*E*)-ethyl 3-(2-bromophenyl)-2,2-difluoro-3-(morpholinoimino)propanoate (**20**). The procedure was operated in general method. The reaction gave 53 mg of (*E*)-ethyl 2,2-difluoro-3-(2-bromophenyl)-3-(morpholinoimino) propanoate in 45 % isolated yield as a pale yellow liquid (PE/EA=10:1). ^1H NMR (500 MHz, CDCl_3): δ 7.61 (d, $J = 8.0$ Hz, 1H), 7.36 (dt, $J = 14.8, 7.5$ Hz, 2H), 7.31 – 7.26 (m, 1H), 4.38 (q, $J = 7.1$ Hz, 2H), 3.61 (t, $J = 4.9$ Hz, 4H), 3.01 (dtd, $J = 17.0, 11.9, 4.7$ Hz, 4H), 1.38 (t, $J = 7.1$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 163.7 (t, $J = 33.9$ Hz), 133.5, 132.7, 131.3, 131.0, 127.2, 127.0, 124.3, 114.2 (t, $J = 248.8$ Hz), 66.3, 62.5, 53.4, 14.1. ^{19}F NMR (471 MHz, CDCl_3): δ -99.6 (d, $J = 268.5$ Hz), -102.8 (d, $J = 268.5$ Hz). HRMS: m/z (EI-TOF) calculated [M]: 390.0391, found: 390.0392.

(*E*)-ethyl 2,2-difluoro-3-(morpholinoimino)-3-(naphthalen-2-yl)propanoate (**21**, *E/Z*=67:33). The procedure was operated in general method. The reaction gave 56 mg of (*E*)-ethyl 2,2-difluoro-3-(morpholinoimino)-3-(naphthalen-2-yl)propanoate in 51 % isolated yield as a pale yellow liquid (PE/EA=10:1). ^1H NMR (500 MHz, CDCl_3) δ 8.37 – 8.26 (m, 1H), 7.99 (s, 1H), 7.92 – 7.86 (m, 2H), 7.63 – 7.45 (m, 3H), 4.41 (q, $J = 7.1$ Hz, 3H), 3.60 (t, $J = 5.0$ Hz, 4H), 2.96 (t, $J = 5.0$ Hz, 4H), 1.40 (t, $J = 7.1$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 163.7 (t, $J = 35.0$ Hz), 140.7 (t, $J = 32.5$ Hz), 133.5, 132.8, 131.3, 128.5, 128.4, 128.4, 127.8, 127.3, 126.8, 125.4, 114.4 (t, $J = 211.3$ Hz), 66.0, 62.6, 54.3, 14.1. ^{19}F NMR

(471 MHz, CDCl₃): δ -101.1. HRMS: m/z (EI-TOF) calculated [M]: 362.1442, found: 362.1439.

(*E*)-ethyl 2,2-difluoro-3-(morpholinoimino)-3-(pyridin-3-yl)propanoate (**22**). The procedure was operated in general method. The reaction gave 38 mg of (*E*)-ethyl 2,2-difluoro-3-(morpholinoimino)-3-(pyridin-3-yl)propanoate in 41 % isolated yield as a pale yellow liquid (PE/EA=5:1). ¹H NMR (500 MHz, CDCl₃) δ 8.71 (s, 1H), 8.65 (d, J = 4.2 Hz, 1H), 7.79 (d, J = 7.8 Hz, 1H), 7.38 (dd, J = 7.8, 4.9 Hz, 1H), 4.38 (q, J = 7.1 Hz, 2H), 3.60 (t, J = 5.0 Hz, 4H), 2.94 (t, J = 5.0 Hz, 4H), 1.37 (t, J = 7.1 Hz, 3H). ¹³C{¹H}NMR (125 MHz, CDCl₃): δ 163.2 (t, J = 31.3 Hz), 150.6, 149.4, 136.2, 127.7, 123.5, 114.00 (t, J = 248.1 Hz), 65.8, 62.7, 54.2, 14.0. ¹⁹F NMR (471 MHz, CDCl₃): δ -101.3. HRMS: m/z (EI-TOF) calculated [M]: 313.1238, found: 326.1237.

(*E*)-ethyl 2,2-difluoro-3-(morpholinoimino)-3-(thiophen-2-yl)propanoate (**23**). The procedure was operated in general method. The reaction gave 21 mg of (*E*)-ethyl 2,2-difluoro-3-(morpholinoimino)-3-(pyridin-3-yl)propanoate in 21 % isolated yield as a pale yellow liquid (PE/EA=7:1). ¹H NMR (500 MHz, CDCl₃) δ 7.64 (s, 1H), 7.26 – 7.23 (m, 1H), 6.96 (d, J = 3.8 Hz, 1H), 4.35 (q, J = 7.1 Hz, 2H), 3.86 (t, J = 5.0 Hz, 4H), 3.16 (t, J = 5.0 Hz, 4H), 1.35 (t, J = 7.1 Hz, 3H). ¹³C{¹H}NMR (125 MHz, CDCl₃): δ 163.2 (t, J = 35.0 Hz), 145.63, 132.6 (t, J = 30.0 Hz), 129.0, 128.4 (t, J = 5.6 Hz), 125.1, 111.6 (t, J = 248.7 Hz), 66.2, 63.4, 51.4, 13.9. ¹⁹F NMR (471 MHz, CDCl₃): δ -93.9. HRMS: m/z (EI-TOF) calculated [M]: 318.0850, found: 318.0848.

(*E*)-ethyl 2,2-difluoro-3-(furan-2-yl)-3-(morpholinoimino)propanoate (**24**). The procedure was operated in general method. The reaction gave 46 mg of (*E*)-ethyl

1
2
3
4 2,2-difluoro-3-(furan-2-yl)-3-(morpholinoimino) propanoate in 51 % isolated yield as a pale
5
6 yellow liquid (PE/EA=7:1). ^1H NMR (500 MHz, CDCl_3) δ 7.40 (s, 1H), 6.77 (dd, $J = 3.4$,
7
8 1.6 Hz, 1H), 6.57 (d, $J = 3.5$ Hz, 1H), 4.38 (q, $J = 7.2$ Hz, 2H), 3.86 (t, $J = 5.0$ Hz, 4H), 3.16
9
10 (t, $J = 5.0$ Hz, 4H), 1.36 (t, $J = 7.1$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 162.3 (t, $J =$
11
12 33.8 Hz), 154.3, 143.5 (t, $J = 33.1$ Hz), 124.8, 113.5, 108.59 (t, $J = 246.9$ Hz), 107.18, 66.2,
13
14 63.5, 51.2, 13.9. ^{19}F NMR (471 MHz, CDCl_3): δ -102.2. HRMS: m/z (EI-TOF) calculated [M]:
15
16 302.1078, found: 302.1076.
17
18
19

20
21 (E)-ethyl-3-(5-(2-ethoxy-1,1-difluoro-2-oxoethyl)thiophen-2-yl)-2,2-difluoro-3-(morpholi
22
23 noimino)propanoate (**25**). The procedure was operated in general method. The reaction gave
24
25 45 mg of
26
27 (E)-ethyl-3-(5-(2-ethoxy-1,1-difluoro-2-oxoethyl)thiophen-2-yl)-2,2-difluoro-3-(morpholin
28
29 oimino)propanoate propanoate in 39 % isolated yield as a pale yellow liquid (PE/EA=7:1).
30
31 ^1H NMR (500 MHz, CDCl_3) δ 7.63 – 7.57 (m, 1H), 7.38 – 7.33 (m, 1H), 4.38 (q, $J = 7.1$ Hz,
32
33 4H), 3.84 (t, $J = 5.0$ Hz, 4H), 2.91 (t, $J = 5.0$ Hz, 4H), 1.37 (t, $J = 7.1$, 3H), 1.36 (t, $J = 7.1$,
34
35 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 162.76 (t, $J = 34.4$ Hz), 162.3 (t, $J = 30.0$ Hz),
36
37 147.72 (t, $J = 31.3$ Hz), 138.9 (t, $J = 33.8$ Hz), 132.0 (t, $J = 3.1$ Hz), 130.2 (t, $J = 1.9$ Hz),
38
39 127.5 (t, $J = 5.6$ Hz), 113.8 (t, $J = 252.5$ Hz), 111.4 (t, $J = 250.0$ Hz), 65.8, 63.7, 63.0, 54.5,
40
41 13.9, 13.9. ^{19}F NMR (471 MHz, CDCl_3): δ -94.2, -102.5. HRMS: m/z (EI-TOF) calculated
42
43 [M]: 440.1029, found: 440.1033.
44
45
46
47
48
49

50
51 (E)-ethyl3-(5-(2-ethoxy-1,1-difluoro-2-oxoethyl)furan-2-yl)-2,2-difluoro-3-(morpholinoi
52
53 mino)propanoate (**26**). The procedure was operated in general method. The reaction gave 68
54
55 mg of
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(*E*)-ethyl 3-(5-(2-ethoxy-1,1-difluoro-2-oxoethyl)furan-2-yl)-2,2-difluoro-3-(morpholinoimino)propanoate in 53 % isolated yield as a yellow liquid (PE/EA=7:1). ¹H NMR (500 MHz, CDCl₃): δ 6.84 (dd, *J* = 3.4, 1.3 Hz, 1H), 6.81 (d, *J* = 3.5 Hz, 1H), 4.38 (q, *J* = 7.1 Hz, 2H), 4.36 (q, *J* = 7.1 Hz, 4H), 3.73 (t, *J* = 5.0 Hz, 4H), 3.07 (t, *J* = 5.0 Hz, 4H), 1.36 (t, *J* = 7.1 Hz, 3H), 1.35 (t, *J* = 7.1 Hz, 3H). ¹³C{¹H}NMR (125 MHz, CDCl₃) δ 163.0 (t, *J* = 31.9 Hz), 161.9 (t, *J* = 33.1 Hz), 145.7 (t, *J* = 34.4 Hz), 144.3, 127.5 (t, *J* = 32.5 Hz), 114.8, 112.9, 112.9 (t, *J* = 124.4 Hz), 108.3 (t, *J* = 248.1 Hz), 66.1, 63.8, 62.8, 53.9, 14.0, 13.8. ¹⁹F NMR (471 MHz, CDCl₃): δ -101.9, -102.8. HRMS: *m/z* (EI-TOF) calculated [M]: 424.1257, found: 424.1258.

(*E*)-ethyl 3-(benzo[*b*]thiophen-3-yl)-2,2-difluoro-3-(morpholinoimino)propanoate (**27**).
The procedure was operated in general method. The reaction gave 47 mg of (*E*)-ethyl 3-(benzo[*b*]thiophen-3-yl)-2,2-difluoro-3-(morpholinoimino)propanoate in 32 % isolated yield as a yellow liquid (PE/EA=7:1). ¹H NMR (500 MHz, CDCl₃) δ 7.91 – 7.84 (m, 1H), 7.80 – 7.73 (m, 1H), 7.52 – 7.46 (m, 2H), 4.48 – 4.32 (m, 4H), 3.59-3.47 (m, 4H), 3.20-2.80 (m, 4H), 1.40 (t, *J* = 7.1 Hz, 3H), 1.35 (t, *J* = 7.1 Hz, 3H). ¹³C{¹H}NMR (125 MHz, CDCl₃) δ 163.6 (t, *J* = 31.9 Hz), 162.2 (t, *J* = 33.7 Hz), 138.5, 138.3, 134.1 (t, *J* = 27.5 Hz), 127.6 (t, *J* = 3.8 Hz), 127.0, 125.7, 124.8, 124.8, 122.4, 114.1 (t, *J* = 247.5 Hz), 111.7 (t, *J* = 250.0 Hz), 66.2, 63.8, 62.7, 53.1, 14.1, 13.8. ¹⁹F NMR (471 MHz, CDCl₃): δ -89.6 (dd, *J* = 9.4, 277.9 Hz), -95.6 (dd, *J* = 4.7, 273.2 Hz), -99.4 (d, *J* = 9.4, 268.5 Hz), -101.6 (dt, *J* = 9.4, 263.8 Hz). HRMS: *m/z* (EI-TOF) calculated [M]: 490.1186, found: 490.1190.

(*E*)-ethyl 2,2-difluoro-3-(1H-indol-3-yl)-3-(morpholinoimino)propanoate (**28**). The procedure was operated in general method. The reaction gave 58 mg of (*E*)-ethyl 2,2-difluoro-3-(1H-indol-3-yl)-3-(morpholinoimino)propanoate in 47 % isolated yield as a

1
2
3
4 yellow liquid (PE/EA=7:1). ^1H NMR (500 MHz, CDCl_3) δ 8.76 (s, 1H), 8.42 (d, $J = 8.1$ Hz,
5
6 1H), 8.06 (s, 1H), 7.39 (d, $J = 8.2$ Hz, 1H), 7.32 (t, $J = 7.6$ Hz, 1H), 7.24 (d, $J = 7.7$ Hz, 1H),
7
8 4.32 (q, $J = 7.1$ Hz, 2H), 3.93 (t, $J = 5.0$ Hz, 4H), 3.22 (t, $J = 5.0$ Hz, 4H), 1.30 (t, $J = 7.1$ Hz,
9
10 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 162.9 (t, $J = 35.6$ Hz), 135.7, 131.3, 125.55, 125.31
11
12 (t, $J = 30.0$ Hz), 125.2, 124.9, 123.8, 121.6, 114.6, 111.4, 111.12 (t, $J = 250.0$ Hz), 66.5, 63.7,
13
14 51.9, 13.9. ^{19}F NMR (471 MHz, CDCl_3): δ -101.0. HRMS: m/z (EI-TOF) calculated [M]:
15
16 351.1397, found: 351.1394.
17
18
19

20
21 (*E*)-ethyl 2,2-difluoro-3-(morpholinoimino)-5-phenylpentanoate (**29**, *E/Z*=88/12). The
22
23 procedure was operated in general method. This compound is known.^{8a} The reaction gave 50
24
25 mg of (*E*)-ethyl 2,2-difluoro-3-(morpholinoimino)-5-phenylpentanoate in 49% isolated yield
26
27 as a clear colorless liquid (PE/EA=10:1). ^1H NMR (500 MHz, CDCl_3): δ 7.30 (q, $J = 7.3$ Hz,
28
29 2H), 7.25 – 7.19 (m, 3H), 4.36 (q, $J = 7.1$ Hz, 2H), 3.76 (t, $J = 5.0$ Hz, 4H), 2.98- 2.94 (m,
30
31 2H), 2.84- 2.81 (m, 2H), 2.77 (t, $J = 5.0$ Hz, 4H), 1.35 (t, $J = 7.1$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125
32
33 MHz, CDCl_3): δ 162.87 (t, $J = 31.3$ Hz), 158.1 (t, $J = 29.4$ Hz), 140.5, 128.6, 128.3, 126.4,
34
35 113.78 (t, $J = 250.6$ Hz), 65.9, 62.7, 54.9, 31.7, 28.8, 14.0. ^{19}F NMR (471 MHz, CDCl_3): δ
36
37 -105.9.
38
39
40
41
42

43
44 (*E*)-ethyl 3-(2,2-dimethylhydrazono)-2,2-difluoro-5-phenylpentanoate (**30**, *E/Z*=80:20).^{9d}
45
46 The procedure was operated in general method. The reaction gave 27 mg of (*E*)-ethyl
47
48 3-(2,2-dimethylhydrazono)-2,2-difluoro-5-phenylpentanoate in 30% isolated yield as a clear
49
50 colorless liquid (PE/EA=30:1). ^1H NMR (500 MHz, CDCl_3) δ 7.35 – 7.27 (m, 2H), 7.25 –
51
52 7.19 (m, 3H), 4.35 (q, $J = 7.1$ Hz, 2H), 3.00 – 2.89 (m, 2H), 2.83 – 2.76 (m, 2H), 2.74 (s, 6H),
53
54 1.36 (t, $J = 7.2$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 163.5 (t, $J = 31.3$ Hz), 147.8 (t, J
55
56
57
58
59
60

1
2
3
4 =30.6 Hz), 140.8, 128.6, 128.25, 126.4, 114.8 (t, $J=247.5$ Hz), 62.5, 46.9, 31.9, 28.6, 14.0. ^{19}F
5
6 NMR (471 MHz, CDCl_3): δ -104.6.
7

8
9 (*E*)-ethyl 2,2-difluoro-3-(morpholinoimino)decanoate (**31**, $E/Z=76:24$). The procedure
10
11 was operated in general method. The reaction gave 49 mg of (*E*)-ethyl
12
13 2,2-difluoro-3-(morpholinoimino)decanoate in 49% isolated yield as a clear colorless liquid
14
15 (PE/EA=10:1). ^1H NMR (500 MHz, CDCl_3) δ 4.36 (q, $J = 7.1$ Hz, 1H), 3.80 (t, $J = 5.0$ Hz,
16
17 4H), 2.85 (t, $J = 5.0$ Hz, 4H), 2.55 – 2.47 (m, 2H), 1.67 - 1.63 (m, 3H), 1.42 – 1.26 (m, 11H),
18
19 0.90 (td, $J = 6.9, 2.6$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 163.1 (t, $J = 31.3$ Hz),
20
21 161.81 (t, $J = 31.3$ Hz), 113.8 (t, $J = 250$ Hz), 65.9, 62.6, 55.0, 31.6, 29.8, 28.7, 26.9, 25.5,
22
23 22.6, 14.0, 14.0. ^{19}F NMR (471 MHz, CDCl_3): δ -106.0. HRMS: m/z (EI-TOF) calculated [M]:
24
25 334.2068, found: 324.2070.
26
27
28
29
30

31
32 (*E*)-ethyl 2,2-difluoro-3-(morpholinoimino)octanoate (**32**, $E/Z=75:25$). The procedure was
33
34 operated in general method. The reaction gave 62 mg of (*E*)-ethyl
35
36 2,2-difluoro-3-(morpholinoimino)decanoate in 68% isolated yield as a clear colorless liquid
37
38 (PE/EA=10:1). ^1H NMR (500 MHz, CDCl_3) δ 4.33 (q, $J = 7.1$ Hz, 2H), 3.78 (t, $J = 5.0$ Hz,
39
40 4H), 2.83 (t, $J = 5.0$ Hz, 4H), 2.52 – 2.45 (m, 2H), 1.68 – 1.58 (m, 2H), 1.38 – 1.29 (m, 7H),
41
42 0.90 (t, $J = 6.9$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 163.1 (t, $J = 31.3\text{Hz}$), 158.6 (t, J
43
44 = 29.4Hz), 113.8 (t, $J = 250.0\text{Hz}$), 65.9, 62.6, 55.0, 32.0, 25.8, 25.2, 22.1, 14.0, 13.8. ^{19}F
45
46 NMR (471 MHz, CDCl_3): δ -106.0. HRMS: m/z (EI-TOF) calculated [M]: 306.1755, found:
47
48 306.1750.
49
50
51
52

53
54 (*E*)-ethyl 2,2-difluoro-3-(morpholinoimino)heptanoate (**33**, $E/Z=83:17$). The procedure
55
56 was operated in general method. The reaction gave 47 mg of (*E*)-ethyl
57
58
59
60

1
2
3
4 2,2-difluoro-3-(morpholinoimino)decanoate in 53% isolated yield as a clear colorless liquid
5
6 (PE/EA=10:1). ^1H NMR (500 MHz, CDCl_3): δ 4.34 (q, $J = 7.1$ Hz, 2H), 3.78 (t, $J = 5.0$ Hz,
7
8 4H), 2.86 – 2.81 (t, $J = 5.0$ Hz, 4H), 2.53 – 2.46 (m, 2H), 1.65 – 1.57 (m, 2H), 1.42 – 1.35 (m,
9
10 2H), 1.33 (t, $J = 7.2$ Hz, 3H), 0.93 (t, $J = 7.3$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ
11
12 163.1 (t, $J = 31.3$ Hz), 158.4 (t, $J = 30.0$ Hz), 113.8 (t, $J = 250.0$ Hz), 66.0, 62.6, 55.0, 27.6,
13
14 26.6, 23.0, 14.0, 13.6. ^{19}F NMR (471 MHz, CDCl_3): δ -106.0. HRMS: m/z (EI-TOF)
15
16 calculated [M]: 292.1598, found: 292.1601.
17
18
19

20
21 (*E*)-ethyl 2,2-difluoro-3-(2-phenylhydrazono)-3-(*p*-tolyl)propanoate (**34**). The procedure
22
23 was operated in general method. The reaction gave 60 mg of (*E*)-ethyl
24
25 2,2-difluoro-3-(2-phenylhydrazono)-3-(*p*-tolyl)propanoate in 60% isolated yield as a clear
26
27 colorless liquid (PE/EA=4:1). ^1H NMR (500 MHz, CDCl_3): δ 7.81 (s, 1H), 7.36 (d, $J = 3.5$ Hz,
28
29 3H), 7.23 (dd, $J = 8.5, 7.4$ Hz, 2H), 6.94 – 6.87 (m, 3H), 4.49 (q, $J = 7.2$ Hz, 2H), 2.45 (s, 3H),
30
31 1.44 (t, $J = 7.2$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 163.6 (t, $J = 32.5$ Hz), 143.0,
32
33 140.6, 136.0 (t, $J = 31.3$ Hz), 130.4, 129.2, 129.1, 123.84, 121.53, 113.9 (t, $J = 245$ Hz), 113.3,
34
35 62.9, 21.5, 14.1. ^{19}F NMR (471 MHz, CDCl_3): δ -101.1. HRMS: m/z (EI-TOF) calculated [M]:
36
37 362.1442, found: 362.1439.
38
39
40
41
42

43
44 (*E*)-ethyl 3-(4-bromophenyl)-2,2-difluoro-3-(piperidin-1-ylimino)propanoate (**35**). The
45
46 procedure was operated in general method. The reaction gave 66 mg of (*E*)-ethyl
47
48 3-(4-bromophenyl)-2,2-difluoro-3-(piperidin-1-ylimino)propanoate in 57% isolated yield as a
49
50 clear colorless liquid (PE/EA=8:1). ^1H NMR (500 MHz, CDCl_3): δ 7.53 (d, $J = 8.4$ Hz, 2H),
51
52 7.35 (d, $J = 8.4$ Hz, 2H), 4.37 (q, $J = 7.1$ Hz, 2H), 2.93 (t, $J = 5.0$ Hz, 4H), 1.50 – 1.41 (m,
53
54 6H), 1.38 (t, $J = 7.1$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 163.8 (t, $J = 31.9$ Hz),
55
56
57
58
59
60

1
2
3
4 135.49 (t, $J = 31.9$ Hz), 131.7, 130.8, 130.4, 123.6, 114.8 (t, $J = 246.9$ Hz) 62.5, 54.8, 24.7,
5
6 23.8, 14.0. ^{19}F NMR (471 MHz, CDCl_3): δ -100.4. HRMS: m/z (EI-TOF) calculated [M]:
7
8 388.0598, found: 388.0590.
9

10
11 (*E*)-ethyl 3-(4-bromophenyl)-2,2-difluoro-3-((4-methylpiperazin-1-yl)imino)propanoate
12
13 (**36**). The procedure was operated in general method. The reaction gave 69 mg of (*E*)-ethyl
14
15 3-(4-bromophenyl)-2,2-difluoro-3-((4-methylpiperazin-1-yl)imino)propanoate in 57%
16
17 isolated yield as a clear yellow liquid (PE/EA=1:1). ^1H NMR (500 MHz, CDCl_3) δ 7.55 (d, J
18
19 = 8.5 Hz, 2H), 7.35 (d, $J = 8.4$ Hz, 2H), 4.37 (q, $J = 7.1$ Hz, 2H), 2.99 (t, $J = 5.0$ Hz, 4H), 2.35
20
21 (t, $J = 5.0$ Hz, 4H), 2.23 (s, 3H), 1.37 (t, $J = 7.1$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3):
22
23 δ 163.6 (t, $J = 31.3$ Hz), 138.0 (t, $J = 31.3$ Hz), 131.9, 130.3, 127.7, 124.1, 114.4 (t, $J = 248.1$
24
25 Hz), 62.6, 53.8, 53.3, 45.6, 14.1. ^{19}F NMR (471 MHz, CDCl_3): δ -101.0. HRMS: m/z (EI-TOF)
26
27 calculated [M]: 403.0707, found: 407.0703.
28
29
30
31
32

33
34 (*E*)-2,2-difluoro-3-(morpholinoimino)-*N*-phenyl-3-(*p*-tolyl)propanamide (**39**).^{8a} The
35
36 procedure was operated in general method. The reaction gave 105 mg of
37
38 (*E*)-2,2-difluoro-3-(morpholinoimino)-*N*-phenyl-3-(*p*-tolyl)propanamide in 93% isolated
39
40 yield as a white solid (PE/EA=5:1), m.p. 131-132 °C. ^1H NMR (500 MHz, CDCl_3): δ 8.00 (s,
41
42 1H), 7.58 (d, $J = 7.8$ Hz, 2H), 7.37 (dt, $J = 7.5, 3.8$ Hz, 4H), 7.22 (d, $J = 7.9$ Hz, 2H), 7.18 (t,
43
44 $J = 7.4$ Hz, 1H), 3.58 (t, $J = 5.0$ Hz, 4H), 2.93 (t, $J = 5.0$ Hz, 4H), 2.38 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR
45
46 (125 MHz, CDCl_3): δ 161.6 (t, $J = 28.9$ Hz), 141.2 (t, $J = 30.6$ Hz), 139.8, 136.5, 129.4, 129.1,
47
48 128.5, 128.5, 125.2, 120.2, 114.37 (t, $J = 251.3$ Hz), 66.0, 54.2, 21.4. ^{19}F NMR (471 MHz,
49
50 CDCl_3): δ -101.2.
51
52
53
54
55

56 Ethyl 2,2-difluoro-3-oxo-3-(*p*-tolyl)propanoate (**40**).^{8a} Compound **3** was added into 25 mL
57
58
59
60

1
2
3
4 round bottom flask with 2 mL THF and 2 mL 0.6 M HCl. After the raw material **3** was
5
6 consumed by TLC under room temperature. The crude production was diluted with ethyl
7
8 ethylate and then scrubber with saturated NaCl solution (3 times). The organic layers dried
9
10 over anhydrous Na₂SO₄, concentrated in vacuo, and purified by flash column chromatograph
11
12 to give the pure production **40** (88%). ¹H NMR (500 MHz, CDCl₃) δ 7.97 (d, *J* = 8.2 Hz, 2H),
13
14 7.31 (d, *J* = 8.1 Hz, 2H), 4.37 (q, *J* = 7.1 Hz, 2H), 2.44 (s, 3H), 1.31 (t, *J* = 7.1 Hz, 3H).
15
16 ¹³C{¹H}NMR (125 MHz, CDCl₃): δ 184.9 (t, *J* = 27.5 Hz), 161.9 (t, *J* = 30.6 Hz), 146.5,
17
18 130.0 (t, *J* = 2.5 Hz), 129.7, 128.5, 109.8 (t, *J* = 263.1 Hz), 63.7, 21.9, 13.8. ¹⁹F NMR (471
19
20 MHz, CDCl₃): δ -107.6.

21
22
23
24
25
26 2,2-Difluoro-3-(morpholinoamino)-3-(p-tolyl)propan-1-ol (**41**).^{8a} **3** was added into 25 mL
27
28 tube with 2 mL anhydrous THF under ice-bath. LiAlH₄ (10 equiv) was gradually added the
29
30 mixture. Then the mixture was stirred under room temperature. After the raw material **3** was
31
32 consumed by TLC. The crude production was diluted with ethyl ethylate and then scrubber
33
34 with saturated NaCl solution (3 times). The organic layers dried over anhydrous Na₂SO₄,
35
36 concentrated in vacuo, and purified by flash column chromatograph to give the pure
37
38 production **41** (PE/EA= 4:1, 74%). ¹H NMR (500 MHz, CDCl₃) δ 7.25 (d, *J* = 6.9 Hz, 2H),
39
40 7.18 (d, *J* = 8.0 Hz, 2H), 4.99 (s, 1H), 4.36 (dd, *J* = 22.5, 4.2 Hz, 1H), 4.00 (ddd, *J* = 29.6,
41
42 12.8, 3.9 Hz, 1H), 3.84 – 3.67 (m, 5H), 3.07 – 2.43 (m, 5H), 2.36 (s, 3H). ¹³C{¹H}NMR (125
43
44 MHz, CDCl₃) δ 138.6, 131.8, 129.2, 128.6, 121.8 (t, *J* = 246.9 Hz), 66.7, 63.4 - 62.0 (m, 2C),
45
46 56.5, 21.1. ¹⁹F NMR (471 MHz, CDCl₃): δ -107.3 (d, *J* = 254.3 Hz), -119.9 (d, *J* = 254.3 Hz).
47
48
49
50
51
52
53

54 (*E*)-2,2-Difluoro-3-(morpholinoimino)-3-(p-tolyl)propan-1-ol (**42**). **3** was added into 25
55
56 mL tube with 2 mL anhydrous THF under ice-bath. NaBH₄ (10 equiv) was gradually added
57
58
59
60

1
2
3
4 the mixture. Then the mixture was stirred under room temperature. After the raw material
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

the mixture. Then the mixture was stirred under room temperature. After the raw material
3 was consumed by TLC. The crude production was diluted with ethyl ethylate and then
scrubber with saturated NaCl solution (3 times). The organic layers dried over anhydrous
Na₂SO₄, concentrated in vacuo, and purified by flash column chromatograph to give the pure
production **42** (PE/EA= 4:1, 62%). ¹H NMR (500 MHz, CDCl₃) δ 7.39 (d, *J* = 8.0 Hz, 2H),
7.21 (d, *J* = 8.0 Hz, 2H), 4.08 (td, *J* = 11.8, 7.2 Hz, 2H), 3.62 (t, *J* = 5.0 Hz, 4H), 3.05 (t, *J* =
7.3 Hz, 1H), 2.90 (t, *J* = 5.0 Hz, 4H), 2.37 (s, 3H). ¹³C{¹H}NMR (125 MHz, CDCl₃): δ 146.4
(t, *J* = 32.5 Hz), 139.7, 129.3, 128.6, 128.1, 118.2 (t, *J* = 240.6 Hz), 66.0, 64.2, 63.9, 63.7,
54.3, 21.4. ¹⁹F NMR (471 MHz, CDCl₃): δ -103.7. HRMS: *m/z* (EI-TOF) calculated [M]:
284.1336, found: 284.1339.

AUTHOR INFORMATION

Corresponding Author

E-mail: qsong@hqu.edu.cn.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENT

Financial support from the National Natural Science Foundation of China (21202049), the
Recruitment Program of Global Experts (1000 Talents Plan), Natural Science Foundation of
Fujian Province (2016J01064), Fujian Hundred Talents Program, the Program of Innovative
Research Team of Huaqiao University (Z14X0047), and Graduate Innovation Fund (for M.
Ke) of Huaqiao University are gratefully acknowledged. We also thank Instrumental Analysis
Center of Huaqiao University for analysis support.

ASSOCIATED CONTENT

Supporting Information

¹H NMR, ¹³C NMR, and ¹⁹F NMR spectra for all products. The Supporting Information is available free of charge on the ACS Publications website.

REFERENCES

1. (a) Filler, R.; Kobayashi, Y.; Yagupolskii, L. M. *Organofluorine Compounds in Medicinal Chemistry and Biomedical Applications*; Elsevier: New York, **1993**. (b) *Organofluorine Chemistry: Principles and Commercial Applications*; Banks, R. E., Smart, B. E., Tatlow, J. C., Eds.; Plenum: New York, **2000**. (c) Hiyama, T.; Kanie, K.; Kusumoto, T.; Morizawa, Y.; Shimizu, M. *Organofluorine Compounds: Chemistry and Applications*; Springer: Berlin, **2000**. (d) Wang, J.; Sánchez-Roselló, M.; Aceña, J. L.; del Pozo, C.; Sorochinsky, A. E.; Fustero, S.; Soloshonok, V. A.; Liu, H. *Chem. Rev.* **2014**, *114*, 2432.

2. (a) Zhu, W.; Wang, J.; Wang, S.; Gu, Z.; Aceña, J. L.; Izawa, K.; Liu, H.; Soloshonok, V. *A. J. Fluorine Chem.* **2014**, *167*, 37. (b) Merino, E.; Nevado, C. *Chem. Soc. Rev.* **2014**, *43*, 6598. (c) Xu, X. H.; Matsuzaki, K.; Shibata, N. *Chem. Rev.* **2015**, *115*, 731. (d) Zhou, Y.; Wang, J.; Gu, Z.; Wang, S.; Zhu, W.; Aceña, J. L.; Soloshonok, V. A.; Izawa, K.; Liu, H. *Chem. Rev.* **2016**, *116*, 422.

3. (a) Muller, K.; Faeh, C.; Diederich, F. *Science* **2007**, *317*, 1881. (b) Begue, J.-P.; Bonnet-Delpon, D. *Bioorganic and Medicinal Chemistry of Fluorine*, Wiley, Hoboken, **2008**. (c) Purser, S.; Moore, P. R.; Swallow, S.; Gouverneur, V. *Chem. Soc. Rev.* **2008**, *37*, 320;

4. (a) Tomashenko, O. A.; Grushin, V. V. *Chem. Rev.* **2011**, *111*, 4475. (b) Furuya, T.; Kamlet, A. S.; Ritter, T. *Nature* **2011**, *473*, 470. (c) Fujikawa, K.; Fujioka, Y.; Kobayashi, A.;

1
2
3
4 Amii, H. *Org. Lett.* **2011**, *13*, 5560. (d) Guo, C.; Wang, R.-W.; Qing, F.-L. *J. Fluorine Chem.*
5
6 **2012**, *143*, 135.

7
8
9 5. (a) Qing, F.-L. *Chin. J. Org. Chem.* **2012**, *32*, 815. (b) Besset, T.; Schneider, C.; Cahard,
10
11 D. *Angew. Chem., Int. Ed.* **2012**, *51*, 5048. (c) Min, Q.-Q.; Yin, Z.; Feng, Z.; Guo, W.-H.;
12
13 Zhang, X. *J. Am. Chem. Soc.* **2014**, *136*, 1230. (d) Ge, S.; Chaladaj, W.; Hartwig, J. F. *J. Am.*
14
15 *Chem. Soc.* **2014**, *136*, 4149.

16
17
18 6. (a) Ge, S.; Arlow, S. I.; Mormino, M. G.; Hartwig, J. F. *J. Am. Chem. Soc.* **2014**, *136*,
19
20 14401. (b) Feng, Z.; Min, Q.-Q.; Zhao, H.-Y.; Gu, J.-W.; Zhang, X. *Angew. Chem., Int. Ed.*
21
22 **2015**, *54*, 1270. (c) Belhomme, M. C.; Besset, T.; Poisson, T.; Pannecoucke, X.; *Chem. Eur.*
23
24 *J.*, **2015**, *21*, 12836. (d) Sato, A.; Han, J.; Ono, T.; Wzorek, A.; Acena, J. L.; Soloshonok, V.
25
26
27
28
29 *A. Chem. Commun.* **2015**, *51*, 5967.

30
31 7. (a) Brehme, R.; Enders, D.; Fernandez, R.; Lassaletta, J. M. *Eur. J. Org. Chem.* **2007**,
32
33 *2007*, 5629. (b) Lazny, R.; Nodzewska, A.; *Chem. Rev.* **2010**, *110*, 1386.

34
35
36 8. (a) Xu, P.; Wang, G.; Zhu, Y.; Li, W.; Cheng, Y.; Li, S.; Zhu, C. *Angew. Chem., Int. Ed.*
37
38 **2016**, *55*, 2939. (b) Xie, J.; Zhang, T.; Sc, M.; Chen, F.; Mehrkens, N.; Rominger, F.;
39
40 Rudolph, M.; Hashmi, A. S. *Angew. Chem., Int. Ed.* **2016**, *55*, 2934.

41
42
43 9. (a) Pair, E.; Monteiro, N.; Bouyssi, D.; Baudoin, O. *Angew. Chem., Int. Ed.* **2013**, *52*,
44
45 5346. (b) Prieto, A.; Jeamet, E.; Monteiro, N.; Bouyssi, D.; Baudoin, O. *Org. Lett.* **2014**, *16*,
46
47 4770. (c) Prieto, A.; Landart, M.; Baudoin, O.; Monteiro, N.; Bouyssi, D. *Adv. Synth. Catal.*
48
49 **2015**, *357*, 2939. (d) Prieto, A.; Melot, R.; Bouyssi, D.; Monteiro, N. *Angew. Chem., Int. Ed.*
50
51 **2016**, *55*, 1885. (e) Prieto, A.; Melot, R.; Bouyssi, D.; Monteiro, N. *ACS Catal.* **2016**, *6*, 1093.

52
53
54
55
56 10. Ke, M.; Feng, Q.; Yang, K.; Song, Q. *Org. Chem. Front.* **2016**, *3*, 150.
57
58
59
60

- 1
2
3
4 11. Morimoto, H.; Fujiwara, R.; Shimuzu, Y.; Morisaki, K.; Ohshima, T. *Org. Lett.* **2014**,
5
6 16, 2018.
7
8
9 12. (a) Dudnik, A. S.; Fu, G. C. *J. Am. Chem. Soc.* **2012**, *134*, 10693. (b) Xu, H.; Zhao, C.;
10
11 Qian, Q.; Deng, W.; Gong, H. *Chem. Sci.* **2013**, *4*, 4022.
12
13
14 13. (a) Fallis, A. G.; Brinza, I. M. *Tetrahedron* **1997**, *53*, 17543. (b) Friestad, G. K.
15
16 *Tetrahedron* **2001**, *57*, 5461. (c) Miyabe, H.; Ueda, M.; Naito, T. *Synlett* **2004**, 1140. (d)
17
18 Friestad, G. K. *Eur. J. Org. Chem.* **2005**, *2005*, 3157. (e) Miyabe, H.; Yoshioda, E.; Kohtani,
19
20 S. *Curr. Org. Chem.* **2010**, *14*, 1254.
21
22
23
24 14. (a) Zhang, G.; Xie, Y.; Wang, Z.; Liu, Y.; Huang, H. *Chem. Commun.* **2015**, *51*, 1850.
25
26 (b) Janson, P. G.; Ilchenko, N. O.; Diez-Varga, A.; Szabó, K. J. *Tetrahedron*, **2015**, *71*, 922.
27
28
29 15. Ros, A.; Lopez-Rodriguez, R.; Estepa, B.; Alvarez, E.; Fernandez, R.; Lassaletta, J. M.
30
31 *J. Am. Chem. Soc.* **2012**, *134*, 4573.
32
33
34 16. Yasushi, K.; Takehiro, Y.; Jun-ya, K.; Teruo, K.; Tadashi, K.; Takeo, I.; Tsutomu, Y.
35
36 *Synthesis* **2014**, *4*, 455.
37
38
39 17. Dubrovskiy, A.V.; Larock, R. C. *J. Org. Chem.* **2012**, *77*, 11232.
40
41
42 18. Breuil-Desvergnès, V.; Gore, J. *Tetrahedron*. **2001**, *57*, 1951.
43
44 19. Xu, P.; Wu, Z.; Zhou, N.; Zhu, C. *Org. Lett.* **2016**, *18*, 1143.
45
46
47 20. Richard, H.; White, H. K.; Irick, G.; *J. Org. Chem.* **1959**, *24*, 1784.
48
49 21. Li, Y. P.; Alexander, M.; Wucherpfennig, A. L.; Yelick, P.; Chen, W.; Stashenko, P.
50
51 *Acta. Cryst.* **2014**, *70*, 935.
52
53
54 22. Dugan, L.; Haendler, H. M. *J. Am. Chem. Soc.* **1942**, *64*, 2502.
55
56
57 23. Savornin, B.; Madadi, N. E.; Delmas, F.; Gasquet, M.; Timon-David, P.; Vanelle, P.;
58
59
60

1
2
3
4 Maldonado, J. J. *Pharm. Pharmacol.* **1991**, *43*, 58.
5

6 24. Popp, F. D. *J. Het. Chem.* **1984**, *21*, 617.
7

8 25. Yoshiya, F.; Akihiro, O.; Mssaya, H.; Naoto, C. *Asian J. Org. Chem.* **2013**, *2*, 1036.
9

10 26. Xu, X., Zavalij, P. Y., Doyle, M. P. *Angew. Chem., Int. Ed.* **2012**, *51*, 9829.
11

12 27. Feng, B.; Cheng, H.; Chen, J.; Deng, Q.; Lu, L.; Xiao, W. *Chem. Commun.* **2014**, *50*,
13
14
15
16 9550.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60